TRIDENT MEDIQUIP LIMITED

REGD. OFFICE: SHOP-2004, 2ND FLOOR, NORTH EXTENSION, FALSAWADI,
NEAR SAHARA DARWAJA, SURAT-395003, GUJARAT
CIN: U33309GJ2019PLC110421
Email: info@tridentmediquip.com Tel.: 0261-2451274/2490224

DIRECTOR'S REPORT

To,
The Members,
Trident Mediquip Limited

Your Directors are pleased to present hereunder the 6th Annual Report of the Company along with Audited Standalone Financial Statement and Auditor's Report thereon for the Financial Year ended March 31, 2025.

1. Financial Performance Of The Company:-

The financial performance of the Company for the year ended on 31st March, 2025 is summarized below:

(Amt. in Lacs.)

PARTICULARS	STANDALONE	
	2024-25	**2023-24**
Total Income	2689.01	3033.51
Total Expenditure other than Financial Costs and Depreciation	2202.73	2546.63
Profit before Financial cost, Depreciation and Exceptional items & Tax (EBITDA)	486.28	487.18
Finance Costs	142.56	134.72
Depreciation	294.60	245.20
Profit/(Loss) before Exceptional and Extraordinary items	49.12	106.96
Profit/(Loss) before Tax	**49.12**	**106.96**
Profit/(Loss) after Tax	**33.92**	**99.41**
Total Comprehensive Income for period	**33.92**	**99.41**
Earnings per share (Basic & Diluted) (in Rs.)	**0.44**	**1.28**

2. Financial Highlights & Operations:

The Key highlights pertaining to the business of the company for the year 2024-25 and period subsequent there to have been given hereunder.

Your Directors inform you that, during the year under review, Your Company has revenue from operations of Rs. 2689.01 Lacs and EBITDA of 486.28 Rs. Lacs as against Rs. 3033.51 Lacs and Rs. 487.18 Lacs respectively in the previous year. During the year under review the Company has earned net profit after tax amounting to Rs. 33.92 Lacs as against Rs. 99.41

TRIDENT MEDIQUIP LIMITED
Amit Bhupendra
DIRECTOR

Lacs in the previous year. The Company's earnings per share were Rs. 0.44 during the current year. Your Directors are hopeful to achieve better financial performance in the coming years.

3. Change in The Nature Of The Business:

During the year under review, there were no changes in the nature of business of the company.

4. Appropriations:

- **Dividend:**

The Board of directors does not recommend a dividend for the year under review.

- **Transfer to Reserve:**

The Board of Directors have not proposed to transfer any amount to any Reserve. Therefore, entire profits of Rs. 33.92 Lakhs earned during the financial year 2024-25 have been retained in profit and loss account.

- **Bonus Shares:**

During the year under review, the Company has not issued bonus shares.

5. Material Changes and Commitment If Any Affecting the Financial Position of the Company Occurred Between the Ends of the Financial Year to Which These Financial Statements Relate and The Date of the Report: -

There are no any material changes and commitment affecting the financial position of the company between the ends of the financial year and the date of the report.

6. Change in Capital: -

During the financial year under review, there is no change in the share capital of the Company.

7. Right Issue:

During the year the Company has not issued any Right shares to its members.

8. Depository System:

As on March 31, 2025, 100% of the Company's total paid-up capital representing 77,80,000 equity shares were in dematerialized form. ISIN of the Equity Shares of your Company is INE0C6Q01019.

TRIDENT MEDIQUIP LIMITED

DIRECTOR

9. **Credit Rating:**

The Company has not obtained Credit Rating from any Credit Rating Agency as on the date of this Report.

10. **Disclosures relating to Holding, Subsidiaries, Joint Ventures and Associate Companies:**

Sr No.	Name of Company	Nature of Relation
1	Trident Lifeline Limited	Holding Company

The Company has no Subsidiaries, Joint Ventures and Associate Company as on 31.03.2025.

The wholly owned subsidiary of the Company, T-Med Biovation Private Limited has been ceased to be wholly owned subsidiary of the Company with effect from 27th March, 2025 due to disinvestment by the Company.

11. **Reconciliation of Share Capital Audit: -**

Pursuant to sub-rule (8) of rule 9A Companies (Prospectus and Allotment of Securities) Rules, 2014, Certificate/Form on half year basis have been issued by a Company Secretary in Practice with respect to due compliance of shares transfer formalities by the company.

The Company Secretary in Practice carried out a Reconciliation of Share Capital Audit to reconcile the total admitted capital with Physical, National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) (collectively 'depositories') and the total issued and listed capital. The audit confirms that the total paid up capital is in agreement with the aggregate of the total number of shares in physical form and in dematerialized form (held with depositories).

13. **Directors and Key Managerial Personnel: -**

As on 31st March, 2025 your Company's Board had 5 members comprising of Executive Directors. The Directors of your Company are well experienced having expertise in their respective fields of technical, finance, strategic and operational management and administration.

In accordance with the provisions of the section 149, 152 and other applicable provisions of the Companies Act, 2013, Mr. Nachiket Raghuvir Amin (DIN: 06762044) Director of the Company will retire by rotation in the ensuing Annual General Meeting and being eligible, offers himself for re-appointment. The Board recommends his re-appointment for the consideration of members of the Company in the ensuing Annual General Meeting.

Brief resume of Mr. Nachiket Raghuvir Amin and his educational/professional qualifications, nature of his working experience, achievements, name(s) of the companies in which he holds Directorships, Memberships and Chairmanships in various Committees and his relationship between directors inter-se are provided the notice convening the 6thAGM of your Company.

TRIDENT MEDIQUIP LIMITED

Amit Bhupendra

DIRECTOR

The Board confirms that none of the Directors of the Company are disqualified from being appointed or continuing as Director in terms of Section 164 of the Companies Act, 2013 and necessary declaration has been obtained from all the Directors in this regard.

The Board also confirms that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as directors of companies by the Board/Ministry of Corporate Affairs or any such statutory authority.

As on March 31, 2025 the composition of the Board and category of directors are as follows:

Sr. No.	Name	DIN	Category	Designation
1	Amit Bhupendra Halvawala	07581835	Promoter, Executive and Non-Independent Director	Chairman
2	Nachiket Raghuvir Amin	06762044	Promoter, Executive and Non-Independent Director	Director
3	Chetan Chandrakant Jariwala	02780455	Promoter, Executive and Non-Independent Director	Director
4.	Hardik Jigishkumar Desai	01358227	Promoter, Executive and Non-Independent Director	Director
5.	Vishal Bhupendra Halvawala	07586519	Promoter, Executive and Non-Independent Director	Director

All the Directors have varied experience and specialized knowledge in various areas of relevance to the Company. The Board consists of directors appointed as per the provisions of the Companies Act, 2013.

Provisions of Section 203 of the Companies Act, 2013 with respect to Key Managerial Personnel (KMP) is not applicable to the Company.

During the year under review, no changes in directorship were made.

After the closure of the financial year following changes were made in directorships:

Mr. Hardik Jigishkumar Desai and Mr. Vishal Bhupendra Halvawala, directors of the Company resigned from their position with effect from 28th April, 2025 due to personal occupancy and other professional commitment.

The Board has placed on record its sincere appreciation for efficient and mature advice by Mr. Hardik Jigishkumar Desai and Mr. Vishal Bhupendra Halvawala, as Director of the Company.

14. Number of Board Meeting Held:

TRIDENT MEDIQUIP LIMITED

Amit Bhupendra

DIRECTOR

The board evaluates all the decisions on a collective consensus. During the year under review, 9 (Nine) Board meetings were held on 22nd April, 2024, 28th June, 2024, 01st July, 2024, 18th July, 2024, 01st August, 2024, 3rd September, 2024, 04th September, 2024, 17th December, 2024 and 13th February, 2025. Also the gap between any two board meetings during this period did not exceed one hundred and twenty days.

The dates for the Board meetings are fixed after taking into account the convenience of all the directors and sufficient notice, in terms of applicable laws, is given to all of them. All the agenda papers for the Board and Committee meetings are disseminated physically to all the directors at least seven days in advance from the date of Board Meetings or on shorter notice whenever required. All the information required for decision making are incorporated in the agenda. The Board reviews the performance of the Company and sets the strategy for future. The Board takes on record the actions taken by the company on all its decisions periodically.

The names of the directors on the Board, their attendance at the Board meetings held during the year and the number of Directorships and Committee Chairmanships/Memberships held by them in other public companies as on 31st March, 2025 are given herein below:

Name of Director	**No. of Board meetings during the year 2024-2025**		**No. of Directorships in other Public Companies**		**No. of Committee position held in other Public Companies**	
	Held during their tenure	**Attended**	**Chair man**	**Member**	**Chair man**	**Member**
Amit Bhupendra Halvawala	9	9	-	1	-	-
Nachiket Raghuvir Amin	9	9	-	-	-	-
Chetan Chandrakant Jariwala	9	9	-	2	-	1
Hardik Jigishkumar Desai	9	9	2	6	1	1
Vishal Bhupendra Halvawala	9	9	-	-	-	-

15. Particulars of Remuneration of Directors and Employees:

The managerial remuneration was paid to the directors during the financial year are as under:

Sr. No.	**Name of Director**	**Designation**	**Managerial Remuneration paid**

TRIDENT MEDIQUIP LIMITED

Amit Bhupendra

DIRECTOR

			(amount in Lacs)
1	Amit Bhupendra Halvawala	Director	72.00
2	Nachiket Raghuvir Amin	Director	Nil
3	Chetan Chandrakant Jariwala	Director	Nil
4	Hardik Jigishkumar Desai	Director	Nil
5	Vishal Bhupendra Halvawala	Director	Nil

16. Appointment of Independent Directors:

Since Company is neither a listed Company nor provisions of Section 149(4) and rules made there under for an appointment of Independent Director is applicable to the Company.

17. Director's Responsibility Statement:

Pursuant to Section 134(5) of the Act, the Board of Directors, to the best of its knowledge and ability, confirm that:

a) In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures if any;

b) They have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for the year under review.

c) They have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.

d) They have prepared the annual accounts on a going concern basis.

e) They have devised proper system to ensure compliance with the provisions of all applicable laws and that such system were adequate and operating effectively.

18. Committees Of Board Of Directors:

The Company is not required to form any Committee under the Companies Act, 2013 and rules made thereunder.

19. Auditors:

a. Statutory Auditors:

M/s. A Bafna & Associates, Chartered Accountants, (Firm Registration No. 121901W) have been appointed as the Statutory Auditors of your Company on 30TH September, 2024 to hold office till conclusion of the 10th AGM to be held in year 2029.

TRIDENT MEDIQUIP LIMITED

Amit Bhupendra

DIRECTOR

The Auditors' Report given by M/s. A Bafna & Associates, Statutory Auditors, on the Financial Statements of your Company, for the year ended 31st March, 2025, forms part of the Annual Report. There is no qualification, reservation or adverse remark or any disclaimer in their Report. The Auditors' Report for the year is self-explanatory & does not contain any modified opinion, hence need no comments.

b. Secretarial Auditor:

Provisions of Section 204 of the Companies Act, 2013 with respect to Secretarial Audit are not applicable to the Company. During the Financial Year, your Company has complied with applicable Secretarial Standards issued by ICSI.

c. Internal Auditor:

Provisions of Section 138 of the Companies Act, 2013 with respect to Internal Auditor are not applicable to the Company.

d. Cost Auditors:

The Company has not appointed the Cost Auditor as pursuant to Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Amendment Rules, 2014, the cost audit is not applicable to the Company.

20. Internal Control Systems And Their Adequacy:

The Internal Control System provides for well documented policies / guidelines, authorizations and approval procedures. The Company has in place adequate internal financial controls with reference to financial statements. During the year, such controls were tested and no reportable material weakness in the design or operation was observed.

21. Risk Management:-

Risk management is embedded in your Company's operating framework. Your Company believes that managing risks helps in maximizing returns. Risk Management is the systematic process of understanding, measuring, controlling and communicating organization's risk exposures while achieving its objectives. Risk Management is an important business aspect in the current economic environment and its objective is to identify, monitor and take mitigation measures on a timely basis in respect of the events that may pose risks for the business. The Company's approach to addressing business risks is comprehensive and includes periodic review of such risks and a framework for mitigating controls and reporting mechanism of such risks. We have established processes and guidelines, along with a strong overview and monitoring framework at the Board and Senior Management levels.

22. Related Parties Transactions.

TRIDENT MEDIQUIP LIMITED

DIRECTOR

There were no any materially significant related parties' transaction with promoters and directors which were in conflict with the interest of the Company attracting the provision of Section 188 of the Companies Act, 2013 during the financial year. Accordingly, the disclosure of related party transactions, as required under Section 134(3)(h) of the Act, in Form AOC – 2, is attached herewith.

23. Extract Of Annual Return:

The company does not have any website, therefore requirement to mention the Web link of Annual Return is not applicable to the company.

24. Particulars Of Loans, Guarantees Or Investments:

During the year under review your Company has complied with the provisions of Sections 185 and 186 of the Act in respect of loans, investments, guarantees and security.

25. Particulars Of Employees:

The Company does not have any employee(s) in receipt of remuneration exceeding the limits specified under Rule 5 (2) of Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014.

26. Equal Employment Opportunities:

Being an equal opportunity employer, the company will do its utmost to ensure that all of its employees are treated fairly during the period of their employment irrespective of their race, religion, sex (including pregnancy), colour, creed, age, national origin, physical or mental disability, citizenship status, ancestry, marital status veteran status, political affiliation, or any other factor protected by law. All decisions regarding employment will be taken based on merit and business needs only.

27. Particulars of Energy Conservation, Technology Absorption and Foreign Exchange Earning And Outgo:

A statement giving details of conservation of energy, technology absorption, foreign exchange earnings and outgo, in accordance with Section 134(3)(m) of the Act, read with the Rule 8(3) of the Companies (Accounts) Rules, 2014, is annexed as **Annexure-A** hereto and forms part of this report

28. Corporate Social Responsibility Policy:

The Company has not developed and implemented any Corporate Social Responsibility initiatives as the said provisions are not applicable to the Company.

TRIDENT MEDIQUIP LIMITED

DIRECTOR

29.Health, Safety & Environment Policy:

The company is committed to provide a safe and conducive work environment to its women employees. During the year under review, there were no cases filed under the sexual Harassment of women at workplace (Prevention, Prohibition and Redressal) Act 2013.

30.Loan from Directors:

During the year under reporting, the Company has taken Rs. **411.15** Lakhs Unsecured Loan from directors and relatives of directors and repaid of Rs. 323.22 Lakhs. Pursuant to rule 2(c)(viii) of the Companies (Acceptance of Deposits) Rules, 2014 declaration has been received from them that the amount has not been given out of the funds acquired by them, either by borrowings or by accepting loans or deposits from others. Refer Note No. 28 of the Financial Statement.

31.General Disclosures:

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review: -

a. Issue of equity shares with differential rights as to dividend, voting or otherwise.
b. Issue of Shares (including sweat equity shares) to employees of the Company under any scheme.
c. No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and Company's operations in future.
d. Since Company is not fall in the category in which formal annual evaluation has been made by the Board of its own performance and that of its committees and individual directors is not included in Board report.
e. Details relating to deposits covered under Section 73 of the Act read with Chapter V of the Act and the Companies (Acceptance of Deposits) Rules, 2014.
f. There was no proceeding initiated/pending against your Company under the Insolvency and Bankruptcy Code, 2016.
g. The Company has not made any one-time settlement for loans taken from the Banks or Financial Institutions, and hence the details of difference between amount of the valuation done at the time of one time settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof is not applicable.

Your director's further state that during the year under review, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition

TRIDENT MEDI[illegible]P LIMITED

DIRECTOR

and Redressal) Act, 2013 and the Company has complied with the provisions of the Maternity Benefit Act, 1961, whenever applicable.

32. Cautionary Statement:

The statements in this Report may be forward looking within the meaning of the applicable securities laws and regulations. Actual results may differ materially from those expressed in the statement. Certain factors that could affect the Company's operations include increase in price of inputs, availability of raw materials, changes in Government regulations, tax laws, economic conditions and other factors.

33. Acknowledgements:

Your directors would like to express their sincere appreciation for the assistance and cooperation received from, government, customers, vendors and members during the year under review. Your directors also wish to place on record their deep sense of appreciation for the committed services by the company's executives, staff and workers.

Your Directors appreciate and value the trust imposed upon them by the members of the Company. The relations between the management and the staff were cordial during the period under review.

Date: 28.04.2025
Place: Surat

For Trident Mediquip Limited

TRIDENT MEDIQUIP LIMITED

DIRECTOR

AMIT B HALVAWALA
Director
(DIN: 07581835)

NACHIKET RAGHUVIR AMIN
Director
(DIN: 06762044)

ANNEXURE-A TO THE DIRECTOR'S REPORT

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

Information under Section 134 (3) (m) of the Companies Act, 2013 read with Rule 8 (3) of the Companies (Accounts) Rules, 2014 for the year ended March 31, 2025 is given below and forms part of the Directors' Report.

A. CONSERVATION OF ENERGY

a. Steps taken for impact on conservation of energy:- NIL

b. The steps taken by the Company for utilizing alternate sources of energy:- NIL

c. The Capital investment on energy conservation equipment- NIL

B. TECHNOLOGY ABSORPTION

a. The efforts made by the Company towards technology absorption.-NIL

b. The benefits derived like product improvement, cost reduction, product development or import substitution:- NIL

c. In case of imported technology (imported during the last three years reckoned from the beginning of the financial year) - Not Applicable

d. The expenditure incurred on Research and Development: Not applicable

C. FOREIGN EXCHANGE EARNINGS AND OUTGO:

The particulars relating to foreign exchange earnings and outgo during the year under review are as under:

(Amount Rs. In Lacs)

Particulars	2024-25	2023-24
Foreign exchange earned	25.25	24.56
Foreign exchange outgo	1.53	1.15

Date: 28.04.2025

Place: Surat

For Trident Mediquip Limited

TRIDENT MEDIQUIP LIMITED

Amit B Halvawala
Director
(DIN: 07581835)

DIRECTOR

Nachiket Raghuvir Amin
Director
(DIN: 06762044)

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

SL. No.	Particulars	Details
a)	Name (s) of the related party & nature of relationship	NA
b)	Nature of contracts/arrangements/transaction	
c)	Duration of the contracts/arrangements/transaction	
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	
e)	Justification for entering into such contracts or arrangements or transactions'	
f)	Date of approval by the Board	
g)	Amount paid as advances, if any	
h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	

2. Details of contracts or arrangements or transactions at Arm's length basis.

Name of Related Party	Nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of the contracts / arrangements / transactions	Salient terms of the contracts or arrangements or transactions including the value, if any:	Amount (Rs. in Lacs)
HAN Enterprise	Directors interest	Purchase	Ongoing	In the Normal Course of Business and at arm's length basis	122.57
Tench Lifesciences LLP	Directors interest	Sale	Ongoing		89.53

TRIDENT MEDIQUIP LIMITED

DIRECTOR

TRIDENT MEDIQUIP LIMITED
For Trident Mediquip Limited

DIRECTOR

AMIT B HALVAWALA	**NACHIKET RAGHUVIR AMIN**
Director	Director
(DIN: 07581835)	(DIN: 06762044)

TRIDENT MEDIQUIP LIMITED

Annual Report

For the Year Ended

31.03.2025

Auditor:

A Bafna & Associates

INDIA

Chartered Accountants

5004, World Trade Centre, Ring Road, Surat (Gujarat) - 395002

Ph: +91- 261- 2302055 Mail- audits@cabafna.in

INDEPENDENT AUDITOR'S REPORT

TO
THE MEMBERS OF TRIDENT MEDIQUIP LIMITED

Report on the Financial Statements

Opinion

We have audited the financial statements of **TRIDENT MEDIQUIP LIMITED** ("the Company"), which comprise the Balance sheet as at 31st March 2025, the statement of Profit and Loss and the Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Accounting Standards specified under section 133 of the Act, of the state of affairs of the Company as at March 31, 2025, its profit/loss and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

A BAFNA & ASSOCIATES
SURAT
FRN 121901W
CHARTERED ACCOUNTANTS

Key audit matters	How our audit addressed the key audit matter
1. Revenue Recognition Refer Note 19 to the Financial Statement Revenue from sale transaction is recognized when goods are dispatched or delivery is handed over to transporter, provided it can be reliably measured and it is reasonable to expect ultimate collection. Revenue is measured at fair value of the consideration received or receivable and is accounted for net of rebates, trade discounts. The estimation of discounts, incentives and rebates recognized, related to sales made during the year, is material and considered to be complex and subject to judgments. The complexity mainly relates to various discounts, incentives and scheme offers, diverse range of market presence and complex contractual agreements/ commercial terms across those markets. Therefore, there is a risk of revenue being misstated as a result of inaccurate estimates of discounts and rebates. Considering the materiality of amounts involved, significant judgments related to estimation of rebates and discounts, the same has been considered as a key audit matter.	**Our Key Procedures Included, But Were Not Limited To, The Following:** **a)** Assessed the appropriateness of the Company's revenue recognition accounting policies, including those relating to rebates and trade discounts by comparing with the applicable accounting standards. **b)** Performed test of details: **i.** Tested, on a sample basis, sales transactions to the underlying supporting documentation which includes goods dispatch notes and shipping documents. **ii.** Reviewed, on a sample basis, sales agreements and the underlying contractual terms related to delivery of goods and rebates to assess the Company's revenue recognition policies with reference to the requirements of the applicable accounting standards. **iii.** Assessed the Company's process for recording of the accruals for discounts and rebates as at the year-end for the prevailing incentive schemes. **iv.** Tested, on a sample basis, discounts and rebates recorded during the year to the relevant approvals and supporting documentation which includes assessing the terms and conditions defined in the prevalent schemes and customer contracts. **c)** Assessed the appropriateness of the Company's description of the accounting policy, disclosures related to discounts, Incentives and rebates and whether these are adequately presented in the standalone financial statements.
2. IT System & Controls Over Financial Reporting The Company's key financial accounting and reporting processes are highly dependent on the controls over the Company's information systems. As such that there exists a risk that gaps in the IT control environment, including automated accounting procedures, IT dependent manual controls and controls preventing unauthorized access to systems and data could result in the financial accounting and reporting records being	**Our Key Procedures Included, But Not Limited To, The Following:** We evaluated and understood the DOS based accounting system adopted by the company. **a)** We assessed IT systems and controls over financial reporting, which included the following: General IT controls design, observation and operation **b)** We assessed the feeding of the data in the system and going through the extraction of the financial information and statements from the IT system existing in the company.

A BAFNA & ASSOCIATES
SURAT
FRN
121901W
CHARTERED ACCOUNTANTS

materially misstated. The IT systems and controls, as they impact the financial recording and reporting of transactions, is a key audit matter and our audit approach could significantly differ depending on the effective operation of the IT controls	**c)** Reviewed the output and reports generated by the system on sample basis. **d)** Where deficiencies were identified, we tested compensating controls or performed alternate procedures. The system needs to be further strengthened for its efficacy to control deficiencies of input/output data from the system

Information Other than the Financial Statements and Auditor's Report thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

A BAFNA & ASSOCIATES
SURAT
FRN
121901W
CHARTERED ACCOUNTANTS

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit

A BAFNA & ASSOCIATES * CHARTERED ACCOUNTANTS * SURAT FRN 121901W

evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in Annexure-A, a statement on matters specified in paragraphs 3 and 4 of the Order.

2. A. As required by Section 143(3) of the Act, we report that:

(a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(b) in our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matters stated in the paragraph 2B(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.;

(c) the Balance Sheet and the Statement of Profit and Loss (including Other Comprehensive Income), Statement of Changes in the Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account;

(d) in our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;

A BAFNA & ASSOCIATES
SURAT
FRN
121901W
CHARTERED ACCOUNTANTS

(e) on the basis of the written representations received from the directors as on 31st March, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2025 from being appointed as a director in terms of Section 164(2) of the Act;

(f) with respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in **"Annexure-B"**; and

(g) The modifications relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2A(b) above on reporting under Section 143(3)(b) of the Act and paragraph 2B(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.

B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements;

ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts; and

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

iv.

a. The management has represented, that, to the best of its knowledge and belief, as disclosed in the accounts, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall:

i. directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Party or

ii. Provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries.

b. Based on such audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (d) (i) and (d) (ii) contain any material misstatement.

v. There has no dividend paid during the period ended 31st March, 2025 by the Company hence, compliance of section 123 of the Act is not arise.

vi. The reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 is applicable from 1 April 2023.

A BAFNA & ASSOCIATES
SURAT
FRN
121901W
CHARTERED ACCOUNTANTS

Based on our examination which included test checks, except for the instances mentioned below, the Company has used accounting softwares for maintaining its books of account, which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective software.

- The feature of recording audit trail (edit log) facility was enabled at the database level to log any direct data changes for the accounting softwares used for maintaining the books of account relating to payroll, consolidation process and certain non-editable fields/tables of the accounting software used for maintaining general ledger.

- The feature of recording audit trail (edit log) facility was enabled at the application layer of the accounting softwares relating to revenue, trade receivables and general ledger for the period 1st April, 2024 to 31st March, 2025 and relating to property, plant and equipment for the period 1 April 2024 to 31st March, 2025.

Further, for the periods where audit trail (edit log) facility was enabled and operated throughout the year for the respective accounting software, we did not come across any instance of the audit trail feature being tampered with

C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act.

The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For A Bafna & Associates
Chartered Accountants
(Firm Reg. No:- 121901W)

Meet P Jain

A BAFNA & ASSOCIATES SURAT FRN 121901W CHARTERED ACCOUNTANTS

CA Meet Prakashkumar Jain
Partner
Membership No:- 195377
UDIN:- 25195377BMHWLT1214
Date: 28.04.2025
Place: Surat

ANNEXURE-A TO THE INDEPENDENT AUDITORS' REPORT

The Annexure referred to in our report to the members of TRIDENT MEDIQUIP LIMITED for the year ended 31st March, 2025.

On the basis of the information and explanation given to us during the course of our audit, we report that:

I. **Property, Plant, Equipment and intangible Assets**

A. The Company is maintaining proper records showing full particulars, including quantitative details and situation of Property, Plant, Equipment and intangible Assets;

B. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, plant and equipment by which all Property, plant and equipment are verified in a phased manner over a period of three years. In accordance with this programme, certain Property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

C. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company.

D. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, plant and equipment (including Right-of-use assets) or Intangible assets or both during the year.

E. According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any Benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

ii. **Inventory**

A. The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were 10% or more in the aggregate for each class of inventory.

B. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned working capital limits in excess of five crore rupees and hence this clause is not applicable to the company.

A BAFNA & ASSOCIATES * SURAT FRN 121901W * CHARTERED ACCOUNTANTS

iii. **Loans given by the Company**

a. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has made investments, provided guarantee or security or granted advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnerships, subsidiaries during the year.

b. According to the information and explanations given to us and based on the audit procedures conducted by us, we are of the opinion that the terms and conditions of the loans given are, prima facie, not prejudicial to the interest of the Company.

c. According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given, the repayment of principal and payment of interest has been stipulated and the repayments or receipts have been regular.

d. According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no overdue amount for more than ninety days in respect of loans given.

e. According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan given falling due during the year, which has been renewed or extended or fresh loans given to settle the overdue of existing loans given to the same party.

f. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not given any loans either repayable on demand or without specifying any terms or period of repayment.

iv. **Loans to directors & Investment by the Company**

According to the information and explanations given to us and on the basis of our examination of the records, the Company has complied with provision of Section 185 and 186 of the Companies Act, 2013 in respect of loans, investments, guarantees and security made. (Refer Note 28D)

v. **Deposits**

According to the information and explanations given to us, and as per our examination of records, the company has not accepted any deposits from public and therefore, the directives issued by the Reserve Bank of India and the provisions of Section 73 to 76 or any other relevant provision of the Companies Act, 2013, and rules framed there under, are not applicable to the company.

vi. **Cost records**

According to the information and explanations given to us, the Central Government has prescribed the maintenance of cost records under Section 148(1) of the Companies Act, 2013 for the products manufactured by it (and/ or services provided by it). Accordingly, provision of clause 3(vi) of the Order is not applicable to the company.

A BAFNA & ASSOCIATES
SURAT
FRN
121901W
CHARTERED ACCOUNTANTS

vii. Statutory Dues:

According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including Goods and Services Tax ('GST'), Provident fund, Employees' State Insurance, Income-tax, Duty of Customs, Cess and other material statutory dues have generally been regularly deposited with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of GST, Provident fund, Employees' State Insurance, Income-tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable.

viii. Unrecorded income

According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.

ix. Repayment of Loans:

a. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest to any lender during the year.

b. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

c. In our opinion, and according to the information and explanations given to us, the term loans have been applied, on an overall basis, for the purposes for which they were obtained.

d. According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the standalone financial statements of the Company, we report that the funds raised on short-term basis have not been used for long-term purposes by the company.

e. According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.

f. According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.

A BAFNA & ASSOCIATES SURAT FRN 121901W CHARTERED ACCOUNTANTS

x. Utilization of IPO & FPO and Private Placement and Preferential issues:

a. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

xi. Reporting of Fraud:

a. Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

b. According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

c. As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

xii. NIDHI Company:

According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

xiii. Related Party Transaction:

In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Sections 177 and 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the AS standalone financial statements as required by the applicable Accounting Standards.

xiv. Internal Audit

According to the information and explanations given to us and according to the size and nature of the business, the company has established the internal audit system as per the provision of section 138 of Companies Act, 2013. Further, the internal audit report of the company have been issued by the internal auditor till the date of the audit report.

xv. Non-Cash Transaction:

In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company

xvi. Register under RBI Act, 1934:

The provisions of Section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause (xvi) (a),(b),(c) & (d) of the Order is not applicable to the Company.

A BAFNA & ASSOCIATES SURAT FRN 121901W CHARTERED ACCOUNTANTS

xvii. Cash Losses

The Company has not incurred cash losses in the current and in the immediately preceding financial year.

xviii. Auditor's resignation

There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

xix. Financial Position

According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

xx. Corporate Social Responsibility

In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

xxi. Qualifications or adverse auditor remarks of group companies

In our opinion and according to the information and explanations given to us, no qualification or adverse remark have been reported in the CARO report of the subsidiary company by the statutory auditor.

For A Bafna & Associates
Chartered Accountants
(Firm Registration No:- 121901W)

Meet P Jain

A BAFNA & ASSOCIATES ★ SURAT FRN 121901W ★ CHARTERED ACCOUNTANTS

CA Meet Prakashkumar Jain
Partner
Membership No:- 195377
UDIN:- 25195377BMHWLT1214

Date: 28.04.2025
Place: Surat

ANNEXURE - B TO THE INDEPENDENT AUDITORS' REPORT

Independent Auditor's Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

1. We have audited the internal financial controls over financial reporting of **TRIDENT MEDIQUIP LIMITED** ("The Company") as of 31 March 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

2. The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

3. Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

A BAFNA & ASSOCIATES
SURAT
FRN
121901W
CHARTERED ACCOUNTANTS

Meaning of Internal Financial Controls over Financial Reporting

6. A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

7. Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For A Bafna & Associates
Chartered Accountants
(Firm Registration No:- 121901W)

Meet P Jain

A BAFNA & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★ SURAT FRN 121901W

CA Meet Prakashkumar Jain
Partner
Membership No:- 195377
UDIN:- 25195377BMHWLT1214

Place: Surat
Date: 28.04.2025

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

[CIN : U33309GJ2019PLC110421]

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Balance Sheet as on 31st March, 2025

Particulars	Note	(Amount in Lacs) As At 31-Mar-2025		(Amount in Lacs) As At 31-Mar-2024	
I. EQUITY AND LIABILITIES					
(1) Shareholder's Funds					
(a) Share Capital	1	778.00		778.00	
(b) Reserves & Surplus	2	136.49		102.58	
Total			914.49		880.58
(2) Share Application Money Pending Allotment					
Total			-		
(3) Non-Current Liabilities					
(a) Long-Term Borrowings	3	1,461.25		752.13	
(b) Long-Term Provisions	4	-		-	
(c) Deferred Tax Liabilities (Net)		-		-	
Total			1,461.25		752.13
(4) Current Liabilities					
(a) Short-Term Borrowings	5	884.69		605.32	
(b) Trade Payables	6	493.81		64.72	
(c) Other Current Liabilities	7	875.48		1,352.22	
(d) Short Term Provisions	8	31.70		33.83	
Total			2,285.68		2,056.09
TOTAL EQUITY AND LIABILITIES			4,661.42		3,688.79
II. ASSETS					
(1) Non-Current Assets					
(a) Property, Plant and Equipment & Intangible Assets	9				
(i) Tangible Assets		1,341.25		1,245.97	
(ii) Intangible Assets		30.00		33.18	
(iii) Capital Work In-Progress		102.50		159.24	
(iv) Intangible Assets Under Development		4.00		4.00	
(b) Non-Current Investments	10	433.07		390.61	
(c) Deferred Tax Assets (Net)	11	51.39		37.49	
(d) Long Term Loans and Advances	12	36.73		45.23	
(e) Other Non-Current Assets	13	296.43		200.23	
Total			2,295.38		2,115.95
(2) Current assets					
(a) Current Investments		-		-	
(b) Inventories	14	953.78		782.04	
(c) Trade Receivables	15	699.94		156.59	
(d) Cash and Cash Equivalents	16	30.90		11.21	
(e) Short-Term Loans and Advances	17	152.20		165.71	
(f) Other Current Assets	18	529.23		457.28	
Total			2,366.04		1,572.84
TOTAL ASSETS			4,661.42		3,688.79

NOTES TO ACCOUNTS

SIGIFICANT ACCOUNTING POLICY 31

As per our report of even date attached.

For A Bafna & Associates
Chartered Accountants
(Firm Reg. No.:121901W)

Meet P Jain

CA Meet Prakashkumar Jain
Partner
Mem. No.: 195377
UDIN : 25195377BMHWLT1214

Place : Surat
Date : 28-04-2025

For And On Behalf Of The Board

TRIDENT MEDIQUIP LIMITED
(Formerly Known As "Trident Mediquip LLP")

AMIT BHUPENDRA HALVAWALA (DIN: 07581835)

NACHIKET RAGUVIR AMIN (DIN: 06762044)

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

[CIN : U33309GJ2019PLC110421]

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Statement of Profit and Loss for the year ended on 31st March, 2025

Particulars	Note	(Amount in Lacs) 2024-25	(Amount in Lacs) 2023-24
I. INCOME			
Revenue From Operations	19	2,129.53	2,058.09
Other Income	20	559.49	975.42
TOTAL INCOME		2,689.01	3,033.51
II. EXPENSES			
Cost of Materials Consumed	21	1,053.65	1,444.20
Purchase of Stock-in-Trade		-	-
Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	22	(40.09)	(150.03)
Employment Benefit Expenses	23	762.12	728.82
Financial Costs	24	142.56	134.72
Depreciation and Amortization Expenses	25	294.60	245.20
Other Expenses	26	427.04	523.63
TOTAL EXPENSES		2,639.89	2,926.55
Profit Before Exceptional and Extraordinary Items and Tax		49.12	106.96
Exceptional Items		-	-
Profit Before Extraordinary Items and Tax		49.12	106.96
Extraordinary Items		-	
Profit Before Tax		49.12	106.96
Tax Expense :			
(1) Current Tax		(28.72)	(43.08)
(2) MAT Credit		-	-
(3) Excess/(Short) Tax Provision of Earlier Year		(0.38)	(1.97)
(4) Deferred Tax		13.90	37.49
Profit for the Year		33.92	99.41
Profit/(Loss) From Discontinuing Operations		-	-
Tax Expense of Discounting Operations		-	-
Profit/(Loss) From Discontinuing Operations		-	-
Balance Transferred to Pre-operative Expenses		-	-
Profit/(Loss) For The Period		33.92	99.41
Earning Per Equity Share:			
(1) Basic		0.44	1.28
(2) Diluted		0.44	1.28

NOTES TO ACCOUNTS
SIGIFICANT ACCOUNTING POLICY 31

As per our report of even date attached.

For A Bafna & Associates
Chartered Accountants
(Firm Reg. No.:121901W)

Meet P Jain

CA Meet Prakashkumar Jain
Partner
Mem. No.:195377
UDIN : 25195377BMHWLT1214

Place : Surat
Date : 28-04-2025

A BAFNA & ASSOCIATES * SURAT FRN 121901W * CHARTERED ACCOUNTANTS

TRIDENT MEDIQUIP LIMITED * SURAT

For And On Behalf Of The Board
TRIDENT MEDIQUIP LIMITED
(Formerly Known As "Trident Mediquip LLP")

Bhupendra

AMIT BHUPENDRA HALVAWALA (DIN: 07581835)	NACHIKET RAGUVIR AMIN (DIN: 06762044)

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

[CIN : U33309GJ2019PLC110421]

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2025

		(Amount Rs. In Lacs) 2024-25		(Amount Rs. In Lacs) 2023-24	
A. CASH FLOW FROM OPERATING ACTIVITIES:		Rs.	Rs.	Rs.	Rs.
Net Profit Before Tax and Extraordinary Items			49.12		106.96
Add:					
Depreciation		294.60		245.20	
Financial Cost		142.56	437.17	134.72	379.93
			486.29		486.89
Less: Other Income (Considered Seprately)			19.06		25.57
Cash from Operations	Total - A		467.23		461.32
Less: Adjustment for Working Capital Changes					
Add/ (Less):					
Increase in Inventory		(171.73)		(109.60)	
Increase in Trade Receivable		(543.35)		79.47	
Increase in Other Current Assets		(71.94)		(188.06)	
Increase in Short Term Loans & Advances		13.51		(23.11)	
Increase in Trade Payable		429.09		(735.25)	
Increase in Other Current Liabilites		(476.74)		(416.09)	
Increase in Short Term Provision		(2.13)		17.87	
	Total - B		(823.30)		(1,374.77)
Cash Generated from Operations after Working Capital Changes (A - B)	(C)		(356.07)		(913.45)
Add: Increase in Non Current Assets			(96.20)		(169.73)
Add: Increase in Long Term Liabilities			-		-
Less: Income Tax			(28.72)		(43.08)
Less: Earlier Year Tax Adjustment			(0.38)		(1.97)
Net Cash Flow from Operating Activities	(D)		(481.37)		(1,128.23)
B. Cash Flow from Investing Activities					
Interest Received		19.06	19.06	25.57	25.57
Add:-					
Sale of Fixed Assets		-		-	
			-		-
Less:					
Increase in Long Term Loans & Advances		(8.50)		8.24	
Investment In Fixed Deposit		43.16		255.66	
Purchase of Equity Shares		(0.70)		-	
Purchase of Fixed Assets		329.97	363.93	821.27	1,085.17
Net Cash Flow from Investing Activities	(E)		(344.87)		(1,059.60)
C. Cash Flow from Financing Activities					
Add: Increase Share Capital			(0.00)		-
Add: Increase in Securities Premium			-		-
Add: Increase in Term Loan			754.81		(20.18)
Less: Decrease in Unsecured Loan			154.40		(360.12)
Add: Increase in Working Capital Facilitities			79.29		329.56
Less: Financial Cost			(142.56)		(134.72)
Net Cash Flow from Financing Activities	(F)		845.93		(185.46)
Net Changes in Cash & Cash Equivalents (D+E+F)			19.69		(2,373.30)
Opening Balance of Cash & Cash Equivalents			11.21		2,384.50
Closing Balance of Cash & Cash Equivalents			**30.90**		**11.21**

A BAFNA & ASSOCIATES SURAT FRN 121901W CHARTERED ACCOUNTANTS

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

[CIN : U33309GJ2019PLC110421]

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2025

AUDITOR'S CERTIFICATE

We have examined the above Cash Flow Statement of **TRIDENT MEDIQUIP LIMITED** (Formerly Known As "Trident Mediquip LLP") for the period ended 31st March, 2025. The Statement has been prepared by the Company in accordance with the Accounting Standard - 3 as issued by Institute of Chartered Accountants of India and in agreement with the corresponding Profit & Loss Account and Balance Sheet of the Company covered by our Report of March 31, 2025 to the members of the Company.

For A Bafna & Associates
Chartered Accountants
(Firm Reg. No.: 121901W)

Meet P Jain

CA Meet Prakashkumar Jain
Partner
Mem. No.: 195377
UDIN : 25195377BMHWLT1214

Place : Surat
Date : 28-04-2025

A BAFNA & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★ SURAT FRN 121901W

TRIDENT MEDIQUIP LIMITED SURAT

For And On Behalf Of The Board
TRIDENT MEDIQUIP LIMITED
(Formerly Known As "Trident Mediquip LLP")

Amit Bhupendra

AMIT BHUPENDRA HALVAWALA
(DIN: 07581835)

NACHIKET RAGUVIR AMIN
(DIN: 06762044)

Notes on Financial Statements for the Year ended 31st March, 2025

The previous year figures have been regrouped / reclassified, wherever necessary to conform to the current year presentation.

1 Share Capital :	(Amount in Lacs) As At 31-Mar-2025		(Amount in Lacs) As At 31-Mar-2024
Authorized Share Capital			
80,00,000 Equity Shares of ₹ 10/- (Each)		800.00	800.00
(Previous Year 80,00,000 Equity Shares of ₹ 10/- Each.)		800.00	800.00
Issued, Subscribed & Paid-up Share Capital			
77,80,000 Equity Shares of ₹ 10/- (Each)		778.00	778.00
(Previous Year 77,80,000 Equity Shares of ₹ 10/- Each Fully Paid)		778.00	778.00

1.1 **77,70,000** Shares out of the issued, subscribed and paid up share capital were allotted as Bonus Shares in the last five years by capitalization of Securities Premium and Reserves.

1.2 Nil Shares out of the issued, subscribed and paid up share capital were allotted in the last five years pursuant to the various Schemes of amalgamation without payment being received in cash.

1.3 Nil Shares out of the issued, subscribed and paid up share capital were allotted on conversion/ surrender of Debentures and Bonds, conversion of Term Loans, exercise of warrants, against Global Depository Shares (GDS) and re-issue of forfeited equity shares, since inception.

1.4 Nil Shares out of the issued, subscribed and paid up share capital held by Subsidiaries do not have Voting Rights and are not eligible for Bonus Shares.

1.5 The details of Shareholders holding more than 5% shares :

Name of Share Holders	As At 31-Mar-2025 No. of Shares	As At 31-Mar-2025 % held	As At 31-Mar-2024 No. of Shares	As At 31-Mar-2024 % held
Trident Lifeline Limited	39,67,800	51.00%	-	-
Nachiket Amin	12,44,875	16.00%	25,02,200	32.16%
Hardik Desai	8,94,625	11.50%	2,46,000	3.16%
Amit Halvawala	6,22,400	8.00%	12,83,700	16.50%
Vishal Halvawala	6,22,400	8.00%	12,83,700	16.50%
Chetan Jariwala	4,27,900	5.50%	8,55,800	11.00%
Total	**77,80,000**	**100.00%**	**61,71,400**	**79.32%**

1.6 Shareholding of Promoters as on 31st March, 2025

Sr. No.	Particulars	No. of Shares	% of Total Shares	% change during the year
1	Trident Lifeline Limited	39,67,800	51.00%	51.00%
2	Nachiket Amin	12,44,875	16.00%	-16.16%
3	Hardik Desai	8,94,625	11.50%	8.34%
4	Amit Halvawala	6,22,400	8.00%	-8.50%
5	Vishal Halvawala	6,22,400	8.00%	-8.50%
6	Chetan Jariwala	4,27,900	5.50%	-5.50%
Total		**77,80,000**	**100.00%**	**20.68%**

1.7 The reconciliation of the number of shares outstanding is set out below :

Particulars	As At 31-Mar-2025 No. of Shares	As At 31-Mar-2025 (Amount in Lacs)	As At 31-Mar-2024 No. of Shares	As At 31-Mar-2024 (Amount in lacs)
Equity Shares at the beginning of the year	77,80,000	778.00	77,80,000	778.00
Add : Shares issued during the year	-	-	-	-
Less : Shares cancelled on buy back of Equity Shares	-	-	-	-
Equity Shares at the end of the year	**77,80,000**	**778.00**	**77,80,000**	**778.00**

2 Reserves & Surplus :	As At 31-Mar-2025		As At 31-Mar-2024	
Securities Premium				
As per Last Balance sheet	-		-	
Add: During the Year	-		-	
		-		-
Profit & Loss A/c & Surplus				
As per Last Balance sheet	102.58		3.17	
Add: Profit for the Year	33.92		99.41	
		136.49		102.58
		136.49		**102.58**

3 Long Term Borrowings :	As At 31-Mar-2025 Non Current	As At 31-Mar-2025 Current	As At 31-Mar-2024 Non Current	As At 31-Mar-2024 Current
Secured				
ICICI Car Loan-I20	-	1.81	1.82	2.24
ICICI Car Loan-Kia Seltos	-	4.54	4.57	3.85
HDFC Loan-Kia Seltos New	12.93	3.83	16.79	3.39
ICICI Car Loan-Asta Grand i10	2.65	1.97	4.63	1.80

A BAFNA & ASSOCIATES
SURAT
FRN 121901W
CHARTERED ACCOUNTANTS

Notes on Financial Statements for the Year ended 31st March, 2025

- ICICI Car Loan-EECO - 1	-	0.93	0.94	1.74
- ICICI Car Loan-EECO - 2	2.44	1.09	3.53	0.97
- ICICI Term Loan - Covid	-	-	-	-
- ICICI Term Loan-Wagon R	1.00	1.89	2.90	1.70
- HDFC Term Loan	264.32	74.33	48.82	-
- HDFC Commercial Vehicle	6.67	3.13	9.82	2.80
- SIDBI Term Loan	260.05	61.92	173.71	24.00
- YES Bank Term Loan	262.22	82.05	-	-
- YES Bank Loan Protector Term Loan	9.99	5.08	-	-
Unsecured				
- From Directors	352.28	-	383.05	-
- From Body Corporate	286.54	-	101.37	-
- From Relatives of Directors	0.16	-	0.16	-
	1,461.25	242.57	752.13	42.49

3.1 Maturity Profile of Term Loans are as set out below :

(Amount in Lacs)

Particulars	Maturity Profile			
	0-1 Years	1-2 Years	2-3 Years	Beyond 3 Years
Secured				
- ICICI Car Loan-I20	1.81	-	-	-
- ICICI Car Loan-Kia Saltos	4.54	-	-	-
- HDFC Loan-Kia Saltos New	3.83	4.06	4.44	4.44
- ICICI Car Loan-Astragrand I10	1.97	2.10	0.55	-
ICICI Car Loan-EECO 1	0.93	-	-	-
ICICI Car Loan-EECO 2	1.09	1.16	1.27	-
- ICICI Term Loan-Wagon R	1.89	1.00	-	-
- HDFC Term Loan	74.33	78.30	85.21	100.81
- HDFC Commercial Vehicle	3.13	3.34	3.33	-
- SIDBI Term Loan	61.92	61.92	61.92	136.21
- YES Bank Term Loan	82.05	82.05	82.05	98.12
- YES Bank Loan Protector Term Loan	5.08	5.00	5.00	-
Unsecured				
- From Directors	-	-	-	352.28
- From Body Corporate	-	-	-	286.54
- From Relatives of Directors	-	-	-	0.16

3.2 We have been informed by the Management of the Company that the Loans from Directors and Related Parties Unsecured Loans are taken with the purview of the Long Term utilization with the condition **"Repayable on Demand"**. However, there may be a case that we have to repay the same in short run on Demand by the Lender Concern.

3.3 The company has not defaulted in repayment of Loans and Interest

3.4

Name of Lender/Type of Loan	Nature of Security	Rate of Interest	Monthly Installments	No of Installment Outstanding
ICICI Car Loan-I20	Hypo. of Vehicle	7.80%	0.21	59
ICICI Car Loan-Kia Saltos	Hypo. of Vehicle	7.66%	0.36	25
HDFC Loan-Kia Saltos New	Hypo. of Vehicle	9.25%	0.42	59
ICICI Car Loan-Astragrand I10	Hypo. of Vehicle	7.70%	0.19	39
ICICI Car Loan-EECO	Hypo. of Vehicle	8.10%	0.16	24
ICICI Car Loan-EECO 2	Hypo. of Vehicle	9.25%	0.11	60
ICICI Term Loan-Wagon R	Hypo. of Vehicle	9.26%	0.17	30
HDFC Term Loan	Hypo. Of Plant & Machinery	8.75%	-	-
- HDFC Bank CC Account	Hypo. Of Stock & Book Debts	8.75%	-	-
HDFC Commercial Vehicle	Hypo. of Vehicle	9.25%	0.32	47
Standard Chartered OD A/C	Hypo. Of Stock & Book Debts	8.75%	-	-
- SIDBI Term Loan	Hypo. Of Plant & Machinery	8.50%	2.00	99

3.5 *The Company has availed the Term Loan & Cash Credit Facility by providing the following properties as collateral securities:- N.A.*

	As At 31-Mar-2025	As At 31-Mar-2024
4 **Long Term Provisions :**		
(As certified by management)		
Provision For Gratuity	-	-
	-	-

A BAFNA & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★ SURAT FRN 121901W

Notes on Financial Statements for the Year ended 31st March, 2025

5 Short Term Borrowings :

Particulars	As At 31-Mar-2025	As At 31-Mar-2024
Working Capital		
- ICICI Bank OD Account	-	(0.42)
- Standard Chartered	-	198.39
- HDFC Bank CC Account	55.30	311.04
- YES Bank CC Account	285.03	-
- EPC Packing Credit	299.86	53.80
Maturity of Long Term Borrowings	242.57	42.49
Credit Card	1.93	0.01
Total	884.69	605.32

5.1 Working capital Facilities are secured by way of hypothecation of Stocks & Book Debts of the company both present and future.
5.2 The company has not defaulted in repyment of Loans and interest

6 Trades Payable :

Particulars	As At 31-Mar-2025		As At 31-Mar-2024	
(As certified by the management)				
Sundry Creditors For Goods & Job Work				
Outstanding For More Than One Year	-		-	
Others	493.81	493.81	64.72	64.72
		493.81		64.72

6.1 Trade Payables ageing Schedule as at 31 March 2025

Particular	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
Micro enterprises and small enterprises	35.21	-	-	-	35.21
Others	458.61	-	-	-	458.61
Disputed dues - Micro enterprises & small enterprises	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Sub total	493.81	-	-	-	493.81
Micro enterprises & small enterprises - Undue					-
Others - Undue					-
Total					493.81

6.2 Trade Payables ageing Schedule as at 31 March 2024

Particular	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
Micro enterprises and small enterprises	31.46	-	-	-	31.46
Others	33.26	-	-	-	33.26
Disputed dues - Micro enterprises & small enterprises	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Sub total	64.72	-	-	-	64.72
Micro enterprises & small enterprises - Undue					-
Others - Undue					-
Total					64.72

6.3 Particulars	As At 31-Mar-2025	As At 31-Mar-2024
(a) the principal amount remaining unpaid to any supplier at the end of accounting year	493.81	64.72
(b) the interest amount remaining unpaid to any supplier at the end of accounting year	-	-
(c) the amount of interest paid by the buyer in terms of section 16 of the MSMED Act, 2006 along with the amount of the payment made to the supplier beyond the appointed day during accounting year	-	-
(d) the amount of interest accrued and remaining unpaid at the end of accounting year	-	-
(e) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act, 2006	-	-
Total	493.81	64.72

7 Other Current Liabilities :

Particulars	As At 31-Mar-2025	As At 31-Mar-2024
Statutory Liabilities	9.20	5.11
Sundry Creditors For Expenses	703.59	1,347.11
Advance received from customer	162.69	-
Total	875.48	1,352.22

A BAFNA & ASSOCIATES * CHARTERED ACCOUNTANTS * SURAT FRN 121901W

Notes on Financial Statements for the Year ended 31st March, 2025

8 Short Term Provisions :	As At 31-Mar-2025		As At 31-Mar-2024	
Provision For Income Tax	28.72		43.08	
Less : Advance Tax	-		(10.00)	
Less : TDS & TCS Receivable	(2.01)		-	
		26.71		33.08
Provision For Expenses		4.99		0.75
		31.70		33.83

10 Non-Current Investments	As At 31-Mar-2025		As At 31-Mar-2024	
I. Investment in Equity				
(a) Investment in Subsidiaries, Associates & Joint Ventures				
- Unquoted Investments				
T-Med Biovation Pvt. Ltd.				
(1 Equity Shares of Rs. 10/- Each)	0.00		0.70	
Total		0.00		0.70
(b) Other than Investment in Subsidiaries, Associates & Joint Ventures		-		-
II. Other Non-Current Investments				
(a) Investment in Fixed Deposits				
- ICICI Bank	3.92		3.65	
Yes Bank	285.00		250.00	
SIDBI Bank	144.15		136.26	
Total		433.07		389.91
		433.07		390.61

11 Deferred Tax Assets (Net) :	As At 31-Mar-2025		As At 31-Mar-2024	
Deffered Tax Assets				
Related to Fixed Assets	51.39		37.49	
Deffered Tax Assets	-		-	
Related to Disallowances as per Income Tax Act.	-		-	
Related to Carried Forward loss and Unabsorbed Depreciation	-		-	
		51.39		37.49
		51.39		37.49

12 Long Term Loans and Advances :	As At 31-Mar-2025	As At 31-Mar-2024
Security Deposit		
a) Secured, Considered Good :	-	-
b) Unsecured, Considered Good :	36.73	45.23
Loans & Advances to Others		
a) Secured, Considered Good :	-	-
b) Unsecured, Considered Good :	-	-
c) Doubtful	-	-
Advance Money Given For Capital Expenditure	-	-
	36.73	45.23

13 Other Non Current Assets :	As At 31-Mar-2025	As At 31-Mar-2024
Exhibition Expenses	116.94	74.71
Research & Development	179.50	125.52
	296.43	200.23

14 Inventories :	As At 31-Mar-2025	As At 31-Mar-2024
(Valued At Cost or N.R.V., whichever is lower)		
Raw Materials & Packing Materials	477.24	345.60
Work-in-progress	-	-
Finished Goods	476.53	436.45
	953.78	782.04

15 Trade Receivables :	As At 31-Mar-2025	As At 31-Mar-2024
Unsecured But Considered Good		
Undisputed Trade Receivables- Considered Good	699.94	156.59
Others	-	-
	699.94	156.59

BAFNA & ASSOCIATES SURAT FRN 121901W CHARTERED ACCOUNTANTS

Notes on Financial Statements for the Year ended 31st March, 2025

15.1 Trade Receivables ageing schedule as at 31 March 2025

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Month - 1 Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Good	570.33			27.93	101.68	699.94
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Good	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Sub total	570.33	-	-	27.93	101.68	699.94
Undue - Considered Good						-
Undue - Considered Doubtful						-
Provision for doubtful debts						-
Total						699.94

15.2 Trade Receivables ageing schedule as at 31 March 2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Month - 1 Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Good	30.16	-	-	48.92	77.51	156.59
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Good	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Sub total	30.16	-	-	48.92	77.51	156.59
Undue - Considered Good						-
Undue - Considered Doubtful						-
Provision for doubtful debts						-
Total						156.59

16 Cash and Cash Equivalent :

	As At 31-Mar-2025		As At 31-Mar-2024	
Cash-in-Hand				
Cash Balance	25.77		11.21	
		25.77		11.21
Bank Balance				
Yes Bank (A/c No. 1183300002099)	5.12		-	
		5.12		-
		30.90		11.21

17 Short Term Loans and Advances :

	As At 31-Mar-2025	As At 31-Mar-2024
Security Deposit		
a) Secured, Considered Good :	-	-
b) Unsecured, Considered Good :	-	-
c) Doubtful	-	-
Short Term Advances to Related Parties		
a) Secured, Considered Good		-
b) Unsecured, Considered Good	52.23	50.15
c) Doubtful	-	-
Short Term Advances to Other Parties		
a) Secured, Considered Good	-	-
b) Unsecured, Considered Good	99.96	115.56
	152.20	165.71

18 Other Current Assets :

	As At 31-Mar-2025	As At 31-Mar-2024
Balance With Revenue Authorities	509.68	450.02
Pre-paid Expenses	19.55	4.08
Interest Receivable	-	3.19
	529.23	457.28

A BAFNA & ASSOCIATES ★ SURAT FRN 121901W ★ CHARTERED ACCOUNTANTS

Notes on Financial Statements for the Year ended 31st March, 2025

9 Property, Plant and Equipment & Intangible Assets :

(Amount In Lacs)

Particulars	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	Value At The Beginning	Addition During The Year	Deduction/ Adjustment	Value At The End	Value At The Beginning	Addition During The Year	Deduction/ Adjustment	Value At The End	W.D.V. As On 31-Mar-25	W.D.V. As On 31-Mar-24
Tangible Assets										
Air Compressor	4.50	-	-	4.50	2.66	0.48	-	3.14	1.36	1.84
Air Conditoner	9.16	-		9.16	5.64	0.91	-	6.55	2.61	3.52
Buliding	217.82	13.69	-	231.51	40.83	17.77	-	58.59	172.92	176.99
Computer	19.94	0.77	-	20.71	16.82	1.89	-	18.71	2.00	3.13
Electirc Fittings	187.49	26.12	-	213.61	85.69	29.19	-	114.87	98.73	101.81
Fire Saftey Equipments	4.65		-	4.65	1.95	0.49	-	2.43	2.21	2.70
Furniture	418.79	4.65	-	423.44	172.09	64.58	-	236.67	186.77	246.70
Office Equipments	9.98	-	-	9.98	5.01	2.23	-	7.23	2.75	4.98
Plant & Machinery	841.50	333.53	-	1,175.03	196.23	147.51	-	343.75	831.29	645.27
Vehicle	97.35		-	97.35	38.31	18.44	-	56.75	40.60	59.04
SUB TOTAL (A)	1,811.17	378.76	-	2,189.94	565.21	283.48	-	848.68	1,341.25	1,245.97
Intangible Assets										
Product Devolpment & Reg.	49.36	6.61	-	55.97	17.51	9.89	-	27.41	28.56	31.84
Documentation	8.28	1.34	-	9.62	6.94	1.23	-	8.18	1.44	1.34
SUB TOTAL (B)	57.63	7.95	-	65.58	24.46	11.13	-	35.58	30.00	33.18
Capital Work-in-progress *(Refer Note 9.1 for Ageing of C.W.I.P.)*										
Building	15.67	-	15.67	-	-	-	-	-	-	15.67
Office Equipments	143.57	102.50	143.57	102.50	-	-	-	-	102.50	143.57
SUB TOTAL (C)	159.24	102.50	159.24	102.50	-	-	-	-	102.50	159.24
Intangible Assets Under Development										
Software Development	4.00	-	-	4.00	-	-	-	-	4.00	4.00
SUB TOTAL (D)	4.00	-	-	4.00	-	-	-	-	4.00	4.00
Total [A+B+C+D] (Current Year)	2,032.05	489.21	159.24	2,362.02	589.66	294.60	-	884.27	1,477.75	1,442.39
Previous Year's Figures	1,210.78	821.27	-	2,032.05	344.46	245.20	-	589.66	1,442.39	866.32

9.1 Ageing of Capital Work-in-progress (Tangible Assets)

Particulars	Amount in CWIP for period of FY 2024-25				31-Mar-25	Amount in CWIP for period of FY 2023-24				31-Mar-24
	Upto 1 Year	1-2 Years	2-3 Years	More Than 3 Years		Upto 1 Year	1-2 Years	2-3 Years	More Than 3 Years	
Projects in progress	102.50	-	-	-	102.50	159.24	-	-	-	159.24
Projects temporarily suspended			-	-	-	-	-	-	-	-
Total	102.50	-	-	-	102.50	159.24	-	-	-	159.24

A BAFNA & ASSOCIATES
SURAT
FRN 121901W
CHARTERED ACCOUNTANTS

Notes on Financial Statements for the Year ended 31st March, 2025

The previous year figures have been regrouped / reclassified, wherever necessary to conform to the current year presentation.

19 Revenue From Operations :

		2024-25		2023-24
Sales (Net of Discount)				
Sales of Products				
Domestic	535.96		25.67	
Export	1,593.57		2,011.25	
Sale - MEIS	-		21.17	
		2,129.53		2,058.09
		2,129.53		2,058.09

20 Other Income :

		2024-25		2023-24
Other Operating Revenue				
Duty Drawback	17.05		24.15	
		17.05		24.15
Indirect Incomes				
Interest Income- Fixed Deposit	13.20		25.08	
Interest Income- Other	5.86		0.49	
Discount Income	1.21		1.32	
Claim Income	522.17		894.94	
Other Income	-		29.44	
		542.44		951.27
		559.49		975.42

21 Cost of Materials Consumed

		2024-25		2023-24
Raw Materials & Packing Material				
Opening Stock	345.60		386.02	
Add: Purchase (Net of Discount and Returns)	1,185.30		1,403.77	
Less : Closing Stock	(477.24)		(345.60)	
		1,053.65		1,444.20
		1,053.65		1,444.20

22 Change in Inventories

		2024-25		2023-24
Stock of Finished Goods				
Opening Stock	436.45		286.42	
Less: Closing Stock	(476.53)		(436.45)	
		(40.09)		(150.03)
		(40.09)		(150.03)

23 Employment Benefit Expenses :

	2024-25	2023-24
Salary & Wages	681.73	634.57
Director Remuneration & Sitting Fees	72.00	72.00
Staff Welfare Expense	2.53	10.00
Contribution to Provident Fund & Other Funds	5.86	12.25
	762.12	728.82

24 Financial Cost :

	2024-25	2023-24
Bank Charges & Loan Processing Charges	11.69	8.56
EPC Packing Credit Interest	14.00	4.40
Interest Expense	51.37	24.99
Interest Expense on Unsecured Loan	45.86	94.74
Interest on TDS	0.30	0.20
Interest Expense on Overdraft Loan	26.88	25.06
Less:- Interest Subsidy	(7.53)	(23.23)
	142.56	134.72

25 Depreciation & Amortized Cost :

	2024-25	2023-24
Depreciation & Amortisation	294.60	245.20
	294.60	245.20

26 Other Expenses :

		2024-25		2023-24
Direct Expenses				
Export Clearing and forwarding	18.52		45.81	
Import Clearing and forwarding	4.53		11.51	
Production Expenses	12.25		19.44	
Freight & Transportation Expenses	-		15.33	
Loading & Unloading Expense	0.89		0.96	
		36.19		93.05

A BAFNA & ASSOCIATES * CHARTERED ACCOUNTANTS * SURAT FRN 121901W

Notes on Financial Statements for the Year ended 31st March, 2025

Administrative, Selling & Other Expenses				
Auditor's Remuneration	0.75		0.75	
Advertisement	0.46		1.60	
Commission Expense	6.74		33.76	
Courier Expense	4.22		5.62	
Computer And Internet Expenses	0.63		0.30	
Custom Duty	2.82		4.97	
Cylinder Expenses	1.46		3.44	
Electricity Expenses	66.85		65.44	
Exhibition Expenses	29.23		18.68	
Exchange Diffrence	5.98		7.63	
Food Expenses	9.21		8.82	
General Expenses	6.20		4.49	
Godown Expenses	0.99		1.15	
Godown Rent	51.19		48.80	
Hardware & Plumbing Expenses	1.04		1.31	
Insurance Expenses	4.45		3.79	
GST Expenses	4.11		4.39	
Laboratory Expenses	19.79		30.98	
Legal, Professional & Consultancy Expenses	46.07		43.28	
Membership & Subscription Fees	0.16		0.34	
Machinery Expenses	13.84		7.42	
Office Expense	3.00		3.77	
Petrol Expense	6.11		9.75	
Packing Expenses	0.59		1.78	
Research & Development Written off	44.87		31.38	
Security Expenses	22.63		15.63	
Stationery & Printing Expenses	3.71		3.56	
Testing Charges	1.35		14.32	
Telephone Expense	1.63		3.62	
Travelling Expenses	27.02		49.13	
Write Off - Balances	2.78		-	
Website Development Charges	0.99		0.67	
		390.85		430.58
		427.04		523.63

26.1 **Payment to Auditors as**

Particulars	Current Year	Previous Year
For Statutory Audit	0.50	0.50
For Tax Audit	0.25	0.25
For GST Fees	-	-
Total	0.75	0.75

26.2 **Interest And Penalty**

Particulars	Current Year	Previous Year
Interest On Late Payment of TDS	0.30	0.20
Total	0.30	0.20

26.3 **Corporate Social Responsibility**

Particulars		Current Year		Previous Year
Corporate Social Responsibility (CSR) expenditure		-		-
Total		-		-
Amount required to be spent by Company during the year:		-		-
Amount of expenditure incurred on*:				
(i) Construction/acquisition of any assets		-		-
(ii) On purposes other than (i) above		-		-
a. promoting health care including preventive health care	-		-	
b. measures for reducing inequalities faced by socially and economically backward groups	-		-	
c. animal welfare	-		-	
Total		-		-
Shortfall at the end of the year		-		-
Total of previous year shortfall		-		-
Reason for shortfall		NA		NA

27 **Additional Regulatory Informations :**

a) The company do not have any immovable property whose title deed are not held in the name of the company

b) The company has not revalued its property, plant & equipment during the year ended March 31, 2025 and year ended March 31, 2024

c) The company has used the borrwoings from banks and financials institutions for the specific purpose for which it was taken at the balance sheet date

d) The company is not declared as wilfiul defaulter by any bank or financial institution or other lenders

e) The company has no transactions with the struck off Companies under Section 248 or 560 on the Act

f) No proceedings were initiated or pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988

g) There are no ultimate beneficiaries to whom the Company has lent / invested nor received any funds during the year within the menaing of Foregin Exchange Management Act 1999 and Prevention of Money Laundering Act 2002

A BAFNA & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★ SURAT FRN 121301W

Notes on Financial Statements for the Year ended 31st March, 2025

h) The Company has compliance related to number of layers prescribed under claue (87) of section 2 on the Companies Act read with the Companies (Restriction on number of Layers) Rules, 2017

i) The Company does not have any charge or satisfaction, which is yet to be registered with the Registrar of Companies beyond the statutory period

j) The Company has not traded in Crypto Currencies or virtual currencies during the year

k) The Company is not required to do expenditure in terms of provisions of Section 135 of the Act on Corporate Social Responsibility.

l) There were no transactions in the Company which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961 (such as search or survey or any other relevant provisions of the Income Tax Act, 1961)

m) There is no Scheme of Arrangments has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013, hence this disclosures is not applicable

n) Details of Foregin Exchange Income & Expenditure

	2024-25	2023-24
Expenses in Foreign Curreny		
Expense In USD	0.49	1.01
Expense In EURO	0.18	0.14
Purchase In USD	0.84	
Purchase In EURO	0.02	
Earnings in Foregin Currency		
Export Sale In USD	19.07	24.56
Commission In USD	6.18	-

o) Details of Government Grants

	[illegible]	2023-24
Capital Subsidy Received during the year (For Plant & Machinery)	-	-
Interest Subsidy Received (adjusted against Term Loan Interest during the year)	7.53	23.23

p) The company has obtained borrowings from the banks against the security of the current assets. The quarterly statements of the current assets filed by the company with the bank are in agreement with the books of accounts.

q) Analytical Ratios
As per sheet attached

r) **EARNINGS PER SHARE**

	Particulars	2024-25	2023-24
1)	Net Profit after tax as per Statement of Profit and Loss attributable to Equity Shareholders (₹)	33.92	99.41
2)	Weighted Average number of equity shares used as denominator for calculating EPS (In Lakhs)	77.80	77.80
3)	Basic and Diluted Earnings per share (₹)	0.44	1.28
4)	Face Value per equity share (₹)	10.00	10.00

28 RELATED PARTY DISCLOSURE

As per Accounting Standard - 18, the disclosure of Transactions with the related parties are given below:

A. **List of Related Parties**

Name	Relationship
Mr. Hardik Desai	Director
Mr. Amit Halvawala	Director
Mr. Chetan Jariwala	Director
Mr. Vishal Halvawala	Director
Mr. Nachiket Amin	Director
Mrs. Ratnaprabha Amin	Relative of Director
Mrs. Shantaben Halvawala	Relative of Director
M/s. T-Med Biovations Pvt. Ltd.	Director's Interest
M/s. Trident Lifeline Limited	Director's Interest
M/s. Talon Healthcare LLP	Director's Interest
M/s. Tench Life Sciences LLP	Director's Interest
M/s. TLL Herbal Limited	Director's Interest
M/s. Tricorp Laboratories Pvt. Ltd.	Director's Interest
M/s. Tricorp Industries Ltd.	Director's Interest
M/s. TLL Parenterals Limited	Director's Interest
M/s. Trident Texofab Limited	Director's Interest
M/s. Han Enterprise	Director's Interest
M/s. Durga Corporation	Director's Interest

A BAFNA & ASSOCIATES
SURAT
FRN 121901W
CHARTERED ACCOUNTANTS

Notes on Financial Statements for the Year ended 31st March, 2025

B. Transaction Entered into with Related Parties with Nature of Relation

Particulars	Name of the Related Party	Relationship	Transaction entered into 2024-25	Transaction entered into 2023-24
- Purchase	M/s. T-Med Biovations Pvt. Ltd.	Director's Interest	-	0.32
	M/s. Han Enterprise	Director's Interest	122.57	-
- Sales	M/s. Tench Life Sciences LLP	Director's Interest	89.53	-
- Purchase of Machinery	M/s. T-Med Biovations Pvt. Ltd.	Director's Interest	-	15.86
- Director's Remuneration	Mr. Hardik Desai	Director	-	16.20
	Mr. Amit Halvawala	Director	72.00	24.00
	Mr. Chetan Jariwala	Director	-	7.80
	Mr. Nachiket Amin	Director	-	24.00
- Interest Paid	Mr. Amit Halvawala	Director	21.58	45.35
	Mr. Nachiket Amin	Director	1.17	4.71
	M/s. Trident Lifeline Limited	Director's Interest	14.32	3.46
	Mr. Vishal Halvawala	Director	3.82	28.59
- Interest Received	M/s. T-Med Biovations Pvt. Ltd.	Director's Interest	5.61	
	M/s. Trident Texofab Limited	Director's Interest	0.25	
- Unsecured Loan Taken	Mr. Hardik Desai	Director	35.00	-
	Mr. Amit Halvawala	Director	140.05	340.35
	Mr. Vishal Halvawala	Director	15.60	118.59
	Mr. Chetan Jariwala	Director	-	8.00
	Mr. Nachiket Amin	Director	10.50	37.71
	M/s. Trident Lifeline Limited	Director's Interest	210.00	104.07
- Unsecured Loan Repaid	Mr. Hardik Desai	Director	60.00	61.50
	Mr. Amit Halvawala	Director	147.03	606.12
	Mr. Vishal Halvawala	Director	25.06	122.04
	Mr. Chetan Jariwala	Director	0.09	8.00
	Mr. Nachiket Amin	Director	26.31	34.16
	M/s. Trident Lifeline Limited	Director's Interest	64.73	63.83
- Loans & Advances Given	M/s. T-Med Biovations Pvt. Ltd.	Director's Interest	2.41	1.50
	M/s. Trident Texofab Limited	Director's Interest	-	-
- Loans & Advances Received	M/s. T-Med Biovations Pvt. Ltd.	Director's Interest	0.56	2.00
	M/s. Trident Lifeline Limited	Director's Interest	-	12.52
	M/s. Trident Texofab Limited	Director's Interest	5.62	-
			1,073.82	1,690.68

C. Outstanding Balances as on Last day of Financial Year for the Related Parties

Particulars	Name of the Related Party	Relationship	O/s Balances of 2024-25	O/s Balances of 2023-24
- Investments	M/s. T-Med Biovations Pvt. Ltd.	Director's Interest	0.00	0.70
- Unsecured Loan	Mr. Hardik Desai	Director	35.99	60.99
	Mr. Amit Halvawala	Director	62.19	47.59
	Mr. Vishal Halvawala	Director	148.77	154.42
	Mr. Chetan Jariwala	Director	84.48	84.57
	Mr. Nachiket Amin	Director	20.84	35.48
	Mrs. Ratnaprabha Amin	Relative of Director	0.16	0.16
	M/s. Trident Lifeline Limited	Director's Interest	187.31	27.71
- Salary Payables	Mr. Hardik Desai	Director	8.19	1.02
	Mr. Amit Halvawala	Director	11.40	1.63
	Mr. Chetan Jariwala	Director	4.55	0.56
	Mr. Nachiket Amin	Director	12.41	2.64
- Other Payables	Mrs. Shantaben Halvawala	Relative of Director	0.19	-
	Mr. Amit Halvawala	Relative of Director	8.63	1.58
	Mr. Nachiket Amin	Director	0.17	0.17
- Payable for Capital Goods	M/s. T-Med Biovations Pvt. Ltd.	Director's Interest	7.38	7.38
- Trade Receivables	M/s. Tench Life Sciences LLP	Director's Interest	89.53	-
- Trade Payables	M/s. Han Enterprise	Director's Interest	41.71	-
			723.91	426.60

D. Loans and Advances given to Related Parties

Type of Borrower	31-Mar-25		31-Mar-24	
	Amount O/S	% of Total	Amount O/S	% of Total
M/s. Trident Texofab Limited	0.23	0.44	5.60	11.17
M/s. T-Med Biovations Pvt. Ltd.	52.01	99.56	44.55	88.83
Total	52.23	100.00	50.15	100.00

29 Segment Reporting

The directors of company evaluates the Group's Performance and allocates resources based on an anaysis of various performance indicators by reportable segments. The Group's reportable segments on the basis of geographical segement are as follows:-

1 India
2 Ghana
3 Kenya
4 Peru
5 Cameroon
6 Venezueala
7 Rest of World

A BAFNA & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★ SURAT FRN 121901W

Notes on Financial Statements for the Year ended 31st March, 2025

The reportable segments derives their revenues from the sale of pharmaceuticals products (Tablets, Capsules, etc.) The Directors reviews revenue as the performance indicator. The measurement of each segment's revenues, expenses and assets is consistent with the accounting policies that are used in preparation of the financial statement.

30 CONTINGENT LIABILITIES AND COMMITMENTS

Particulars	31-Mar-25	31-Mar-24
Contingent Liabilities		
Claims against the company not acknowledged as debt;	-	-
Guarantees		
Other money for which the company is contingently liable.	-	-
Commitments shall be classified as		
Estimated amount of contracts remaining to be executed on capital account and not provided for;	-	-
Uncalled liability on shares and other investments partly paid	-	-
Other commitments	-	-
Total	-	-

As informed by the Management of the company and as per our observation under audit, no commitments against the company is pending on which provision is required to be made or deferred for the current financial year.

For A Bafna & Associates
Chartered Accountants
(Firm Reg. No.:121901W)

CA Meet Prakashkumar Jain
Partner
Mem. No.:195377
UDIN : 25195377BMHWLT1214

Place : Surat
Date : 28-04-2025

For And On Behalf Of The Board
TRIDENT MEDIQUIP LIMITED
(Formerly Known As "Trident Mediquip LLP")

AMIT BHUPENDRA HALVAWALA
(DIN: 07581835)

NACHIKET RAGUVIR AMIN
(DIN: 06762044)

TRIDENT MEDIQUIP LIMITED

Notes forming part of the Balance sheet and Profit and loss account as at 31st March, 2025

❖ **NOTE:- 31**

1. BACKGROUND OF THE COMPANY

The company was originally formed & incorporated as a Limited Liability Partnership at Surat, Gujarat under the Companies Act, 2013 under the name and style of "Trident Mediquip LLP" vide certificate of incorporation in 2020 bearing LLP Identitification Number AAD-4030 issued by the Registrar of Companies, Ahmedabad, Gujarat. Subsequently, the LLP was converted into Public Limited Company and the name of the company was changed to Trident Mediquip Limited pursuant to issuance of Fresh Certificate of Incorporation dated October 19th, 2020 by Registrar of Companies, Ahmedabad, Gujarat. The Corporate Identification Number of our company U33309GJ2019PLC110421.

The Company deals in manufacturing of the medicinal devices. The product portfolio of the company comprises of vide range of I V Cannula, Infusion Giving Set, Measure Volume Set, Blood Transmission Set.

2. SIGNIFICANT ACCOUNTING POLICIES :

A. BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared in accordance with the applicable Accounting Standards notified under Section 133 of the Companies Act, 2013 read with Rule 7 of Companies (Accounts Rules), 2014 under historical cost convention on accrual basis. All the assets and liabilities have been classified as current or non-current as per Company's normal operating cycle and other criteria set out in the Schedule-III to the Companies Act, 2013. Based on the nature of activities, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

B. USE OF ESTIMATES

The preparation of the financial statements is in conformity with Indian GAAP (Generally Accepted Accounting Principles) which requires the management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as on the date of the financial statements. The estimates and assumptions made and applied in preparing the financial statements are based upon management's best knowledge of current events and actions as on the date of financial statements. However, due to uncertainties attached to the assumptions and estimates made actual results could differ from those estimates. Any revision to accounting estimates is recognised prospectively in current and future periods.

C. PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS

(i) Tangible Assets

Property, plant and equipment are stated at historical cost less accumulated depreciation, and accumulated impairment loss, if any. Historical cost comprises of the purchase price including duties and non-refundable taxes, borrowing cost if capitalization criteria are met, directly attributable expenses incurred to bring the asset to the location and condition necessary for it to be capable of being operated in the manner intended by management and initial estimate of decommissioning, restoring and similar liabilities.

A BAFNA & ASSOCIATES CHARTERED ACCOUNTANTS SURAT FRN 121901W

Subsequent costs related to an item of property, plant and equipment are recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are recognized in statement of profit and loss during the reporting period when they are incurred.

An item of property, plant and equipment is derecognized on disposal or when no future economic benefits are expected from its use or disposal. The gains or losses arising from de-recognition are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is de-recognized.

Tangible assets are stated at cost net of recoverable taxes, trade discounts and rebates and machinery including any claims, less accumulated depreciation and impairment loss, if any. The cost of tangible assets comprises for its purchase price, borrowing cost and any other cost directly attributable to bringing the asset to its working condition for its intended use. Subsequent expenditures related to an item of tangible assets are added to its book value only if they increase the future benefits from the existing assets beyond its previously assessed of standard performance.

(ii) Intangible Assets

Intangible assets include software / application which are developed and are measured on the basis of cost incurred for its development. The cost of intangible assets in our business combination is the capitalized value of the cost incurred to develop the asset till it is put to use. Such costs include salary of professional personnel hired, project expenses, research costs, etc. Following initial recognition, intangible assets are carried at cost less any accumulated amortization.

An item of intangible asset is derecognized on disposal or when no future economic benefits are expected from its use or disposal. The gains or losses arising from de-recognition are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized. Subsequent costs related to intangible assets are recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

D. DEPRECIATION, AMORTISATION AND DEPLETION

Depreciation is calculated using the Straight Line value method over their estimated useful lives after deducting residual value of the asset. The estimates of useful lives of tangible assets are as follows:

Class of Assets	Useful life as per schedule II	Useful Life as per Group
Computer	3 years	3 years
Furniture and Fixtures	10 years	10 years
Office Equipment	5 years	5 years
Electrical Installation	10 years	10 years
Intangible Assets	10 Years	10 Years
Vehicles	8 years	3 years

A BAFNA & ASSOCIATES SURAT FRN 121901W CHARTERED ACCOUNTANTS

E. **IMPRAIRMENT OF ASSETS**

Assessment is done at each Balance Sheet date as to whether there is any indication that a tangible asset might be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash flows from other assets or other group of assets, is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of asset/ cash generating unit is made.

Assets whose carrying value exceeds their recoverable amount are written down to recoverable amount. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each Balance Sheet date as to whether there is any indication that an impairment loss recognized for an asset in prior accounting period may no longer exist or may have decreased.

F. **INVESTMENTS**

Current investments are carried at lower of cost and quoted/fair value, computed category-wise. Long-term investments stated at cost. Provision for diminution in the value of Long-term investment is made only if such a decline is other than temporary.

G. **INVENTORIES**

Inventories of traded goods are valued at lower of cost and net realizable value. Cost comprises of all costs of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost formula used is FIFO. Net realizable value is the estimated selling price in the ordinary course of business, less estimated cost necessary to make the sale.

H. **REVENUE RECOGNITION**

Revenue is recognised only when risks and rewards incidental to ownership are transferred to the customer, it can be reliably measured and it is reasonable to expect ultimate collection. Revenue from operations includes sale of goods, services and sales during trial run period, adjusted for discounts (net), and gain/loss on corresponding hedge contracts.

Interest income is recognised on a time proportion basis taking into account outstanding and the interest rate applicable.

I. **EMPLOYEE BENEFITS**

(i) Short-term employee benefits

Short term employee benefits are recognised as an expense at the undiscounted amounted in the statement of Profit and loss for the year which includes benefits like salary, wages, bonus and are recognised as expenses in the period in which the employee renders the related service

(ii) Post-employment benefits:

Defined Contribution Plan

The Company has Defined Contribution Plans for Post-employment benefits in the form of Provident Fund for all employees which are administered by Regional Provident Fund Commissioner. Provident Fund and Employee State Insurance are classified as defined contribution plans as the Company has no further

A BAFNA & ASSOCIATES SURAT FRN 121901W CHARTERED ACCOUNTANTS

obligation beyond making the contributions. The Company's contributions to Defined Contribution plans are charged to the Statement of Profit and Loss as and when incurred.

Defined benefit Plans

Unfunded Plan: The Company has a defined benefit plan for Post-employment benefit in the form of Gratuity. Liability for the above defined benefit plan is provided on the basis of valuation, as at the Balance Sheet date, carried out by an independent actuary. The actuarial method used for measuring the liability is the Projected Unit Credit method.

J. **BORROWING COSTS**

Borrowing costs are interest, commitment charges and other costs incurred by an enterprise in connection with Short Term/ Long Term borrowing of funds. Borrowing cost directly attributable to acquisition or construction of qualifying assets are capitalized as a part of the cost of the assets, upto the date the asset is ready for its intended use. All other borrowing costs are recognized in the Statement of Profit and Loss in the year in which they are incurred.

K. **INCOME TAXES**

Tax expense for the year comprising current tax & deferred tax are considered in determining the net profit for the year. Provision is made for current tax based on tax liability computed in accordance with relevant tax laws applicable to the Company. Provision is made for deferred tax for all timing difference arising between taxable incomes & accounting income at currently enacted or substantively enacted tax rates, as the case may be. Deferred tax assets (other than in situation of unabsorbed depreciation and carry forward losses) are recognized only if there is reasonable certainty that they will be realized and are reviewed for the appropriateness of their respective carrying values at each Balance Sheet date. Deferred tax assets, in situation of unabsorbed depreciation and carry forward losses under tax laws are recognised only to the extent that where is virtual certainty supported by convincing evidence that sufficient future taxable income will be available against which such deferred tax assets can be recognised. Deferred Tax Assets and Deferred Tax Liability are been offset wherever the Company has a legally enforceable right to set off current tax assets against current tax liability and where the Deferred Tax Asset and Deferred Tax Liability relate to Income taxes is levied by the same taxation authority.

L. **EARNINGS PER SHARE**

The earnings in ascertaining the Company's EPS comprises the net profit after tax attributable to equity shareholders and includes the post-tax effect of any extraordinary items. The number of shares used in computing basic EPS is the weighted average number of shares outstanding during the year.

Diluted earnings per share is computed by dividing the profit/(loss) after tax attributable to Equity Shareholders (including the post-tax effect of extra ordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares which could have been issued on conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. Dilutive potential equity shares are determined independently for each period.

A BAFNA & ASSOCIATES SURAT FRN 121901W CHARTERED ACCOUNTANTS

TRIDENT MEDIQUIP LIMITED

Notes forming part of the Balance sheet and Profit and loss account as at 31st March, 2025

M. **PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS**

(i) Provisions

A provisions is recognized when the company has a present obligation as a result of past event, if it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of obligation.

(ii) Contingent Liability

Contingent Liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only on the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

(ii) Contingent Assets

Contingent Assets are neither recognised nor disclosed in the financial statements.

N. **CASH & CASH EQUIVALENTS**

Cash & cash equivalents comprise cash and cash on deposit with banks and corporations. The company considers all highly liquid investments with a remaining maturity at the date of purchase of six months or less and that are readily convertible to known amount of cash to be cash equivalents.

For A Bafna & Associates
Chartered Accountants
(Firm Reg. No.121901W)

CA. Meet Prakashkumar Jain
Partner
Mem. No. 195377

For TRIDENT MEDIQUIP LIMITED
(Formerly Known As Trident Mediquip LLP)

Director
Amit Bhupendra Halvawala
(DIN No.-07581835)

Director
Nachiket Raghuvir Amin
(DIN No: 06762044)

Place : Surat
UDIN : 25195377BMHWLT1214
Date :- 28.04.2025

TRIDENT MEDIQUIP LIMITED (Formerly Known As "Trident MEDIQUIP LLP")

Analytical Ratio Sheet

Particulars	Ratio Parameters	FY 2024-25			FY 2023-24			%	Reasons for Variance
		Numerator	Denominator	Ratio	Numerator	Denominator	Ratio	Variance	
a) Current Ratio	Current Assets / Current Liabilities	2,366.04	2,285.68	1.04	1,572.84	2,056.09	0.76	35.32%	Due to increase in current assets
b) Debt Equity Ratio	Total Outside Liabilities / Shareholders Funds	3,746.92	914.49	4.10	2,808.21	880.58	3.19	28.48%	Due to increase in shareholders funds
c) Debt Service Coverage Ratio	(NPAT+DEP+Interest on TL) / (Int on TL + Repayment of TL)	379.90	293.95	1.29	369.60	67.48	5.48	-76.40%	Due to increase in Repayment of Term Loan
d) Return of Equity Ratio	NPBT / Average Shareholders Fund	49.12	897.54	0.05	106.96	830.87	0.13	-57.49%	Due to decrease in net profit
e) Inventory Turnover Ratio	Revenue from Operations / Average Inventory	2,129.53	867.91	2.45	2,058.09	727.24	2.83	-13.30%	No major variance
f) Trade Receivable Turnover Ratio	Net Credit Sales / Average Trade Receivables	2,129.53	428.27	4.97	2,058.09	196.33	10.48	-52.57%	Due to higher receivable level in the year
g) Trade Paybale Turnover Ratio	Net Credit Purchases / Average Trade Payables	1,185.30	279.27	4.24	1,403.77	432.35	3.25	30.72%	Due to decrease in business during the year
h) Net Capital Turnover Ratio	Net Annual Sales / Average Working Capital	2,129.53	80.36	26.50	2,058.09	(483.25)	(4.26)	-722.22%	Due to increase in average working capital
i) Net Profit Ratio	NPAT / Revenue from Operations	33.92	2,129.53	0.02	99.41	2,058.09	0.05	-67.02%	Due to decrease in net profit
j) Return of Capital Employed	EBIT / Capital Employed	173.53	2,375.74	0.07	251.95	1,632.70	0.15	-52.67%	Due to high increase in capital employed
k) Return on Investment	NPBT / Average Shareholders Fund	49.12	897.54	0.05	106.96	830.87	0.13	-57.49%	Due to decrease in net profit

A BAFNA & ASSOCIATES * CHARTERED ACCOUNTANTS * SURAT FRN 121901W

TRIDENT MEDIQUIP LIMITED
(Formerly Known As "Trident Mediquip LLP")

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Detailed List of Schedules As On 31st March, 2025

Particulars	(Amount In Rs.) As On 31-03-2025
Share Capital	
Trident Lifeline Limited	396.78
Nachiket Amin	124.49
Hardik Desai	89.46
Amit Halvawala	62.24
Vishal Halvawala	62.24
Chetan Jariwala	42.79
	778.00
Unsecured Loan	
A. Loans From Directors:	
Hardik Desai	35.99
Amit Halvawala	62.19
Vishal B Halvawala	148.77
Chetan Jariwala	84.48
Nachiket R Amin	20.84
	352.28
B. Loans From Body Corporate:	
Trident Lifeline Limited	187.31
Dynamic Softlink Private Ltd.	92.49
JD Polytex PVT LTD.	6.75
	286.54
Loans From Relatives of Directors:	
Ratnaprabha Amin	0.16
	0.16

Sundry Creditors For Goods (Raw Material & Packing Material)	O/s For More Than One Year	O/s For Less Than One Year	Total
Apex Techno Polymer Pvt Ltd.	-	4.52	4.52
Amisha Vinyls Pvt Ltd.	-	7.05	7.05
Amcor Flexibles India Pvt Ltd	-	24.52	24.52
Alok Masterbatches Pvt Ltd.	-	0.15	0.15
Connell Bros Company Pvt Ltd.	-	0.19	0.19
Han Enterprise	-	41.71	41.71
H M Corporation	-	3.41	3.41
ILIFE Medical Devices Pvt Ltd.	-	4.23	4.23
I Con Flexipack Pvt Ltd.	-	2.68	2.68
Ambica Industries	-	2.97	2.97
Jog Enterprises	-	0.16	0.16
Kameshwar Packing	-	1.32	1.32
Kasat Plastic	-	5.89	5.89
Orlando Healthcare	-	369.68	369.68
Igaku Needles Private Limited	-	3.87	3.87
Rainbow Industries (INDIA)	-	1.94	1.94
Rainbow Industries India Pvt Ltd.	-	7.76	7.76
Rudraksh Packaging Industires	-	1.96	1.96
Shree Hari Polymers	-	6.63	6.63
Super Star Industries	-	0.40	0.40
Shree Ram Packaging Industries	-	0.79	0.79
Trident Elastomers	-	0.10	0.10
G S Printers	-	1.87	1.87
	-	493.81	493.81

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Detailed List of Schedules As On 31st March, 2025

Particulars	(Amount In Rs.) As On 31-03-2025
Statutory Liabilities	
TDS Payable	5.69
GST Payable- RCM	0.68
Professional Tax	2.50
TCS Payable	0.32
	9.20
Creditors for Rent	
Maltiben Narendrakumar Galiyawala	0.83
Narendra Navinchandra Galiyawala	0.83
	1.67
Creditors for Salary	
Abdullah Shabbir Bhai Raja	0.09
Aayush V Patel	0.55
Ajay R Patel	0.13
Ajeet Sing	0.16
Akshay Padvi	0.17
Alpaben V Patel	0.55
Aman Yadav	0.14
Amit Halvawala - Salary	11.40
Anilkumar Singh	0.14
Anjanikumar Thakur	0.14
Ankita Patra	0.14
Arvind Kumar Moulding	0.31
Arvind Kumar	0.11
Ashutosh Mishra	0.16
Ashfaq Shaikh	0.20
Asmita Thakor	0.17
Atmiya Sopariwala	0.21
Bhagvati K Vasava	0.05
Bhavesh Chhibubhai Patel	0.10
Bhavesh Rameshbhai Patel	0.36
Bhavesh Rathod	0.01
Bhavin Sumanbhai Rathod	0.11
Brijesh Kumar Bhawdwaj	0.08
Chandan Kumar	0.71
Chagan Patel	0.11
Chaitali Rathod	0.17
Chetan Gulab Borse	0.21
Chetan Jariwala Salary	4.55
Dakshaben N Patel	0.11
Deep Rajeshbhai Patel	0.16
Denisha Kumbhani	0.15
Dhiren Bhavsar	0.22
Dip Patel	0.14
Divya Rathod	0.09
Divyeshsinh Rajendrasinh Vasiya	0.13
Farida Aziz Kaukawala	0.15
Ganpat Singh Rathore	0.40
Gaurav Mishra	0.03
Geeta Rathod	0.11
Vidit Handa	0.12
Hansha Rathod	0.11

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Detailed List of Schedules As On 31st March, 2025

Particulars	(Amount In Rs.) As On 31-03-2025
Harshadbhai Dhansukhbhai Dhimmar	0.11
Hardik Desai -Salary	8.19
Hashmita Rathod	0.14
Heeralal Raghuraj	0.07
Hetna S Patel	0.15
Hiren Girishbhai Rathod	0.07
Jagrutiben Kiranbhai Rathod	0.10
Jagdish Wagh	0.18
Jay Sankar	0.20
Jay Kaccha	0.15
Jaysingh Rathod	0.10
Jay Sanjaybhai Bhosale	0.16
Kamal Kumar	0.17
Karan Bharatkumar Desai	0.25
Kaushika Patel	0.08
Kaushik Vasava	0.07
Kishan Rathod	0.09
Kokani Vaishalikumari Jamubhai	0.11
Krishna Yadav	0.22
Kusum Rathod	0.07
Laxmi Patel	0.15
Madhuben	0.14
Maita Dhedgya Gamit	0.09
Bharat Mali	0.19
Rajni Malik	0.12
Mukesh Kumar	0.26
Mukeshkumar B Parmar	0.14
Munawar Ansari	0.29
Nachiket Amin Salary	12.41
Nagendra V Yadav	0.40
Naresh Dhimmar	0.09
Navin Raju Halpati	0.11
Nayan Dhimmar	0.07
Nidhi Dinesh Patel	0.31
Nitish Kumar	0.17
Nitaben Shankarbhai Rathod	0.09
Patel Ayushi N	0.15
Patel Dev	0.15
Patil Hemant Kailashbhai	0.06
Pawan Kumar	0.15
Payal M Rathod	0.10
Poonam Bholeram	0.10
Pratham Bardoliwala	0.20
Prashant Mohanbhai Wagh	0.14
Prashant Patil	0.21
Prakash Singh	0.15
Prem Chaudhry	0.14
Prince Kumar	0.42
Rahul Bharatbhai Rathod	0.05
Rajendra Hasmukhbhai Lad	0.10
Rajjan	0.17
Rakshit	0.15
Ram Ashish Verma	0.52
Ramfal Yadav	0.14
Pardeep Rathi	0.17

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Detailed List of Schedules As On 31st March, 2025

Particulars	(Amount In Rs.) As On 31-03-2025
Ravi Gavit	0.04
Ravi Kumar	0.21
Ravendra Singh	0.16
Ravi Vallabhbhai Pansuriya	0.08
Revaben Rathod	0.10
Rohan N Khoja	0.32
Roshan Singh	0.74
Rudramani Tripathi	0.25
Rupal Bandhara	0.38
Sagar Wagh	0.07
Sakib Yahya Chinwala	0.30
Samir Shaikh	0.08
Santosh Chaudhary	0.11
Sanjay Kumar	0.36
Sanju Maurya	0.15
Sandeep Rajbhar	0.05
Satyanand Singh	0.31
Shaishav Chauhan	0.22
Shaikh Mohammed Nasir	0.12
Shitalben Daivanbhai Gamit	0.07
Shruti Sanghani	0.18
Saurabh Kumar Gupta	0.12
Sushil Kumar	0.36
Shyam Ji	0.05
Siddheshwar Ananda Gade	0.17
Simran Patel	0.16
Sonal Rathod	0.09
Sujoy Das	0.34
Akash Sunil Gayakwad	0.17
Ukkadbhai Sureshbhai Rathod	0.08
Suresh Kumar	0.15
Suraj N Dasari	0.46
Thakor Harsh Jagdishbhai	0.14
Tushar Bante	0.19
Vaibhavbhai Bhikhubhai Rathod	0.11
Vaishnavkumar Thakurbhai Patel	0.15
Vaibhav Vinodbhai Halpati	0.16
Vansh Rohit Atubhai	0.07
Varsha M Hadpati	0.11
Vinod Sharma	0.22
Vinci	0.18
Vishal Bhoopendra Singh	0.15
Vyoma Dhivar	0.20
Yugandhar Shahare	0.28
Zahir Zuber Mulla	0.08
Zuned Zuber Mulla	0.05
	60.65

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Detailed List of Schedules As On 31st March, 2025

Particulars	(Amount In Rs.) As On 31-03-2025
Creditors for Expenses	
Ambica Engineers	0.83
Amit Halvawala - Reimbursement	8.63
A.P Engineering	5.49
ARA Enterprise	1.52
A S Manpower Suppliers	3.26
Bharat Daglia	0.05
B.Marfatia & Co	0.08
Best Tools	0.65
Bhagwati Textile (BHAGWATI)	0.49
Bardoliwala Stationery	0.54
Care Taker Logistic	0.34
DHL Express (I) Pvt Lt	0.05
D N Transport	0.01
Dusberi Trading PLC	535.70
Global Air	2.11
Globe Bio Care	0.12
GLR Laboratories Pvt. Ltd.	0.16
HalimBhai Tileswala	1.92
Hi Care Services Pvt. Ltd	0.03
R.R.Patel Industrial Gases Pvt. Ltd.	0.29
Isha Roadways	0.41
Jaipur Polymers	0.06
Jai Sainath Textile (RAHUL)	0.43
Kalpesh Laxmikant Doshi	28.53
Laminart	2.46
Lemore Logistics	0.08
Lotus Corportation	0.12
Mahabir Enterprise	0.17
Mahalaxmi Textile (NARESH)	0.49
Maruti Enterprise	0.89
Marutinandan Packaging	0.04
Matrix LAB	0.17
Medtech India Enterprises	0.05
Mehta General Store	0.48
Mentor Freight International Pvt. Ltd.	0.20
Miracle Industries	0.01
Mould Tools	0.15
M/S Mohanlal Kacharabhai Mehta	0.22
M/S Shantaben T. Halvawala Purchase	0.19
Nachiket R Amin - REIMBURSE	0.17
Nandini Steel	0.12
New Microtek Precision Punches	1.36
Outofbox India Pvt. Ltd.	0.02
Parimal Trading (PARIMAL)	0.43
Patel Infotech	0.05
Phonenix India Rubber Products	0.01
Pioneer	0.21
P K Textiles	1.93
P & R Automation & Electricals	1.10
Pranav Oxygen	0.04
Pushp Ply	0.85
A Bafna & Associates	0.46
Amareliya & Associates	0.02
Raj Zinc Platers	0.29
Ramilaben Manubhai Rawal	0.00

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Detailed List of Schedules As On 31st March, 2025

Particulars	(Amount In Rs.) As On 31-03-2025
R D Enterprises	0.44
S R Express	0.00
Ridhima Crane Service	0.55
Riddhi Engineers	0.47
Roshni Rubber Stamp C/O Yogesh H Modi	0.01
RRR Automation	0.14
Rudraksha Hotels Pvt Ltd	0.06
Sabdarhusain Nawasali Shaikh	1.77
Intajul Sabul Mohd Shaikh	0.04
Sharan Interior Designer	0.25
Sharma Scientific Instruments	0.19
Shree Offset Printers	0.38
Shri Radhey Krishna Traders	3.04
Shree Sai Enterprises	8.67
Shree Sawariya Seth Terpainter And White Oil Depot	0.18
Shree Vraj Plastic Rec.Mfg	0.20
Skai Air Control Pvt Ltd	8.06
Skytec Equipments	0.36
S R Indian Corporation	0.45
Sri Devki & Sons	0.60
Suhel Enterprises	0.27
Tara Trading Company	0.70
Techno Welds (Vapi)	0.03
T-Med Biovations Pvt Ltd	7.38
Travel Log	1.58
Unick Plastic Systems Pvt Ltd	0.11
United Safeway India	0.02
Vande Bharat Security Forse	0.40
V D & Sons	0.03
Venus Chemical Center	0.45
	641.27
Advance Received from Customers	
Avacare Tanzania Pharmaceutical	6.59
Bateel Drug Store LLC	2.21
CCGlobalcure Pharmaceutical Company Ltd.	1.60
CND Africa Ltd.	0.51
DE BIG DAN Concept NIG Ltd.	17.09
Joaomed Comercio DE Materials Cirurgicos SA	66.64
Labor Import Comercial IMP EXP LTDA	4.35
Royalmed Medical Surgical Equipment	0.21
Royal Pharma 2011 Uganda Ltd.	11.45
TAU MEDICA SRL	0.31
Victoria Healthcare Ltd.	25.20
Biurette Nigera Limited	26.51
	162.69
Provision For Expenses	
Electricity Payable	4.24
Audit Fee Payable	0.75
	4.99

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Detailed List of Schedules As On 31st March, 2025

Particulars	(Amount In Rs.) As On 31-03-2025
Security Deposit	
Bhagwati M Takaiwala Rent Deposit	1.75
CDSL- Security Deposit	0.10
CST Deposit	0.10
DGVCL HT Connection Security Deposit	19.80
Dharmendra Purusottam Katariawala	0.75
Excel Formualtions Cylinder Deposit	0.28
Maltiben Narendrakumar Galiyawala Rent	2.50
Narendra Navinchandra Galiyawala Rent	2.50
Naresh J Takaiwala Rent Deposit	1.75
Pinkal Kikaganeshwala Rent Deposit	5.10
Pranav Oxygen Deposite	0.20
Primal M Takaiwala Rent Deposit	0.75
R.R Industrial Gases Pvt Ltd Deposit	0.40
Rahul N Takaiwala Rent Deposit	0.75
	36.73

Trade Receivables	O/s For More Than Six Months	O/s For Less Than Six Months	Total
Alpha Pharma Unique Ltd	27.93	-	27.93
Gladlab Supplies Ltd	14.08	-	14.08
Infinite Health Limited	-	22.67	22.67
Lacure International	-	414.05	414.05
Ningbo Shimaotong International Co Ltd	65.38	-	65.38
Nazir Abdali LTD.	-	24.78	24.78
Suministros Y Distr Ivan Quintanill A	-	19.08	19.08
Tench Life Sciences LLP	-	89.53	89.53
Textiles Zahir S.A.	-	0.21	0.21
Visrom Company Limited	22.22	-	22.22
	129.61	**570.33**	**699.94**

Loans & Advances to Related Parties (Short Term)	
T-Med Biovations Pvt Ltd	52.01
Trident Texofab Ltd	0.23
	52.23

Advance to Creditors	
A P Technologies ASIA PTE LTD	17.09
Bpcl E Cms Fleet Business	0.00
Disha Engineering	1.50
Flomic Global Logistics Ltd	0.05
Hi-Tech Medicare Devices Pvt Ltd	0.10
Polyone Polymers India Pvt. Ltd.	0.02
Tech India Automation	3.21
J Akar Constructions	4.29
Marudhar Interior	5.00
Precision Tool Industries	0.78
R Wadiwala Securities Pvt Ltd	0.00
V S Automation	4.83
	36.88

TRIDENT MEDIQUIP LIMITED

(Formerly Known As "Trident Mediquip LLP")

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat- 395003

Detailed List of Schedules As On 31st March, 2025

Particulars	(Amount In Rs.) As On 31-03-2025
Advance For Capital Goods	
Pentagon Assembly Automation Pvt Ltd	43.17
	43.17
Advance to Employees	
Eklavya Kumar	4.09
Vishal D Athawale	1.11
Jai Prakash Yadav	0.28
Jignesh Saraiya	1.05
Kishan Nanubhai Rathod	0.02
Monu Kumar	0.57
Pinkesh R Mistry	1.24
Piyush Bhikhabhai Rathod	0.02
Sanjay Kapoor	0.17
Sandipbhai Devidas Panpatil	0.34
Sunil M. Jariwala	10.00
Viralkumar Kanubhai Patel	0.98
Vishalbhai Manubhai Patel	0.04
	19.91
Balance With Revenue Authorities	
CGST Recievable	52.95
SGST Recievable	407.45
IGST Receivable	4.59
GST Refund Receivable	44.70
	509.68
Prepaid Expenses	
Prepaid Insurance	18.35
Prepaid Barcode	0.07
Prepaid Interest	1.13
	19.55